[go: up one dir, main page]

WO2024110625A1 - Agents thérapeutiques à base de cralbp dirigés contre des troubles rétiniens - Google Patents

Agents thérapeutiques à base de cralbp dirigés contre des troubles rétiniens Download PDF

Info

Publication number
WO2024110625A1
WO2024110625A1 PCT/EP2023/082964 EP2023082964W WO2024110625A1 WO 2024110625 A1 WO2024110625 A1 WO 2024110625A1 EP 2023082964 W EP2023082964 W EP 2023082964W WO 2024110625 A1 WO2024110625 A1 WO 2024110625A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
cralbp
seq
protein
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/082964
Other languages
English (en)
Inventor
Achim Stocker
Walter AESCHIMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of WO2024110625A1 publication Critical patent/WO2024110625A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the present invention relates to compositions for use in methods of preventing or treating diseases or disorders caused by an endogenous retinoid deficiency of an animal or a human, wherein said compositions comprise complexes comprising (a) a CRALBP protein, and (b) a cognate ligand of CRALBP.
  • the present invention relates to the prevention and treatment of retinal diseases and disorders such as Retinitis Pigmentosa and related diseases and disorders by administration, preferably via intravitreal application, of the described CRALBP based compositions and complexes effecting the recovery of light-sensitive photoreceptors within the eye’s retina.
  • the retinoid or visual cycle is described as a cyclic enzymatic pathway that continuously generates 11-cz -retinal, the chromophore of visual pigments in rod and cone photoreceptor cells needed for vision (Maeda, T., et al., 2009, Hum. Molec. Genet. 18: 2277-2287; Kiser, P.D. et al., 2014, Chem. Rev. 114: 194-232; Kiser, P.D., et al., 2021, Journal of Biological Chemistry 296: 100072).
  • l l -cz.s retinal is the photon-absorbing partner of opsins in cone and rod photoreceptor cells of the vertebrate eye.
  • Absorption of a photon is coupled to cis- ⁇ o-trans photoisomerization in the retinylidene moiety, deactivating the photopigment.
  • Regenerative trans- o-cis recycling does not occur in the rod and cone photoreceptor cells, but instead in adjacent retinal pigment epithelium (RPE) and Muller cells.
  • RPE retinal pigment epithelium
  • IRBP interphotoreceptor retinol binding protein
  • RPE all-trans-retinol is acylated by lecithin retinol acyltransferase (LRAT) yielding al 1 -// zzz.s-reti ny 1 ester. This ester is concomitantly hydrolyzed and isomerized by the enzyme (RPE65) to form 11 -cis-retinol.
  • LRAT lecithin retinol acyltransferase
  • the highly light sensitive l l -cz.s retinol is then taken up by CRALBP chaperoning its oxidation to 1 1 -cz.s retinal by cis-specific retinol dehydrogenase (RDH5) and the reloding process of the rod and cone photoreceptor cells with the freshly regenerated chromophore.
  • RDH5 cis-specific retinol dehydrogenase
  • retinal diseases or dystrophies in particular, inherited retinal diseases or dystrophies including retinitis pigmentosa (RP) (Shintani K., et al., 2009, Optometry 80:384-401; Maeda, T., et al., 2009, Hum. Molec. Genet. 18: 2277-2287; O'Neal, T.B., et al., 2022, In: StatPearls. Treasure Island (FL): StatPearls Publishing), Leber congenital amaurosis (LCA) (Kumaran N., et al., 2017, Br. J. Ophthalmol.
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • COD cone dystrophy
  • CPD cone-rod dystrophy
  • RPA retinitis punctata albesciens
  • CSNB fundus albipunctatus and cone stationary night blindness
  • retinal diseases or dystrophies are typically associated with a breakdown of light-detecting rod and cone photoreceptor cells over time, destroying vision (Moiseyev, G., et al., 2005, Proc. Nat. Acad. Sci. 102: 12413-12418). There is currently no cure for any of these diseases or dystrophies. Common symptoms include impaired night vision and a loss of peripheral fields leading to tunnel vision, and eventual blindness.
  • Retinitis pigmentosa is the most common group of inherited retinal diseases worldwide. It is characterized by progressive photoreceptor degeneration with subsequent degeneration of the retinal pigment epithelium (RPE) (Hartong, D.T. et al., 2006, Lancet, 368: 1795-1809; Shintani K., et al., 2009, Optometry 80:384-401). There are a variety of forms of RP all of which show various limitations of visual performance over time and the course and progression of the disease show considerable variability between individuals.
  • RPE retinal pigment epithelium
  • RP is typically characterized by initial symptoms of night blindness, with onset in adolescence or early adulthood, loss of peripheral vision and, as the disease progresses, loss of central vision that can lead to blindness or severe visual impairment.
  • the age-at-onset of symptoms is highly variable and ranges from childhood to mid-adulthood.
  • RP disease classification can be by made by age of onset, for example, congenital RP (sometimes referred to as LCA), juvenile onset RP, teenage onset RP, adult onset RP, and late onset RP.
  • Electroretinogram (ERG) responses are an early indicator of loss of rod and cone function in RP and diminution of ERG responses can be evident within the first few years of life, even though symptoms appear much later.
  • Typical RP presents as primary degeneration of rods, with secondary degeneration of cones, and is consequently described as a rod-cone dystrophy, with rods being more affected than cones. This sequence of photoreceptor involvement explains why some RP subjects initially present with night blindness, and only in later life become visually impaired in all light conditions.
  • RP can be caused by defects in many different genes and their related disease pathways. At present, more than 200 causative RP mutations have been detected in more than 100 different genes. RP genotypes are heterogeneous, and RP subjects with the same mutation can exhibit different phenotypes. RP may be classified by inheritance type, for example, autosomal dominant (ad) RP, autosomal recessive (ar) RP, X-linked (XL) or sex-linked recessive RP, sporadic RP (simplex RP; most are recessive), or digenic RP. RP is currently estimated to affect at least 300,000 individuals worldwide, of which approximately 20%-30% are autosomal recessive (arRP).
  • arRP autosomal recessive
  • LCA Leber congenital amaurosis
  • Retinitis Punctata Albesciens is a form of RP that exhibits a shortage of l l -cz.s- retinal in the rods.
  • LRAT is the fourth gene involved in the visual cycle that may cause a white-dot retinopathy (Littink et al., Ophthalmology, 119: 1899-906 (2012)).
  • Congenital Stationary Night Blindness (CSNB) and Fundus Albipunctatus are a group of diseases that are manifested as night blindness, but there is not a progressive loss of vision as in RP. Some forms of CSNB are due to a delay in the recycling of 1 l-czs-retinal. Fundus Albipunctatus has been shown to be also a progressive disease although much slower than RP. It is caused by gene defects that lead to a delay in the cycling of l l-czs-retinal, including heterozygous mutations in RPE65 (Schatz et al., Ophthalmology, 118:888-94 (2011)).
  • Age-related macular degeneration is the leading cause of blindness in the western world.
  • atrophic AMD represents a slowly progressing neurodegenerative disorder in which specialized neurons (rod and cone photoreceptors) die in the central part of the retina called the macula.
  • Histopathological and clinical imaging studies indicate that photoreceptor degeneration in dry AMD may be triggered by abnormalities in the retinal pigment epithelium (RPE) that lies beneath photoreceptors and provides crucial metabolic support to these lightsensing neuronal cells.
  • RPE retinal pigment epithelium
  • There is no FDA-approved treatment for the most prevalent dry (atrophic) form of AMD (Petrukhin, K., et al., 2013, Drug Discovery Today:Therapeutic Strategies 10: l,el l-e20).
  • an exogenous chromophore 9-cv.s-retinyl acetate
  • 9-cv.s-retinyl acetate an exogenous chromophore, 9-cv.s-retinyl acetate
  • An open-label phase lb trial with patients aged 6 years or older with LCA and RPE65 or LRAT mutations showed that the treatment was well tolerated and resulted in clinically meaningful improvements in visual function in most patients (Koenekoop, R. K., et al., 2014, Lancet 384: 1513-1520; WO 2013/134867).
  • no follow-up studies have ever since been reported.
  • the present invention relates to the use of CRALBP based compositions and complexes for the treatment of multiple groups of retinal diseases and disorders that are, in particular caused by endogenous retinoid deficiency.
  • treatment using compositions comprising mono-, di- or oligomeric complexes of either wild-type or engineered CRALBP mutant protein with its cognate ligand, preferably with its cognate cisretinoid can overcome endogenous retinoid deficiency.
  • the abrogation of the enzyme’s activity in the RPE65-/- mouse is characterized by the virtual absence of l l -cv.s retinal chromophore regeneration and related absence of light-sensitive rod photoreceptors i.e. a hallmark of impaired vision (Maeda, T., et al., 2009, Invest Ophthalmol Vis Sci. 50(9):4368-78).
  • In vitro and in vivo restoration of lightsensitive rod photoreceptors in such mouse model is a strong indicator for the high biological potency of the treatment.
  • the compositions and complexes used in the present invention and acting as storage devices for an efficient and safe delivery of the retinoids, preferably cisretinoids, to the retinal photoreceptors, are efficiently addressing retinoid deficiencies of the retina.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, preferably of said human, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cA-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein preferably said disease or disorder is a retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cA-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a retinal disease or disorder of an animal, preferably of a human, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cA-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, preferably of said human, wherein said disease or disorder is a retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cA-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is an inherited retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cv.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is an inherited retinal disease or disorder associated with a retinoid deficiency of the retina of said animal, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cv.s-retinoid.
  • said disease or disorder is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said disease or disorder is RP.
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • AMD age-related macular degeneration
  • STGD Stargardt disease
  • COD cone dystrophy
  • CCD cone-rod dystrophy
  • RPA retinitis punctata albesciens
  • CSNB cone stationary night blindness
  • the present invention provides a composition for use in a method of maintaining or improving visual function in an animal, preferably in a human, having an endogenous retinoid deficiency, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of maintaining or improving visual function in an animal, preferably in a human, having a retinoid deficiency of the retina, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of reducing or preventing chromphore depletion in an animal, preferably in a human, having an endogenous retinoid deficiency, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of reducing or preventing chromphore depletion in an animal, preferably in a human, having a retinoid deficiency of the retina, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • said endogenous retinoid deficiency is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), preferably dry AMD, Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said endogenous retinoid deficiency is RP.
  • said animal is a human.
  • said retinoid deficiency of the retina is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), preferably dry AMD, Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said endogenous retinoid deficiency is RP.
  • said animal is a human.
  • said CRALBP protein has an amino acid sequence selected from group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28.
  • FIG. 1 Close up view of the mobile gate region of CRALBP (closed conformation) with the position and orientation of the di-cysteine A212C:T250C mutation highlighted as sticks. Mutations were introduced using Coot and side chain rotamers arranged using the program’s rotamer library. Distances of 1.9 - 3.1 A between the terminal sulfhydryl groups of C212 and C250 are conducive with disulfide bond (2.05 A) formation under oxidizing conditions. 3-D overlay with the X-ray structural model (loiz.pdb) of the mobile gate moiety of the apo-form of alpha-TTP illustrates the extent of the conformational change between the closed and the open state.
  • FIG. 2 Close up view of the in silico model of the mobile gate region of the four mono di-cysteine mutants of CRALBP with the position of the formed di-sulfide bonds highlighted as sticks.
  • FIG. 3 Close up view of the in silico model of the mobile gate region of the three double and the triple di -cysteine mutant of CRALBP with the position of the formed di-sulfide bonds highlighted as sticks.
  • FIG. 4 Superposition of all in silico di-cysteine mutant models showing four possible di-sulfide bonds across the mobile gate.
  • FIG. 5 Chromatogram of preparative GFC on a Superdex® 200 26/60 after loading CRALBP with 9-cz.s-retinal.
  • Panel A shows wild-type CRALBP and panel B the di-cysteine mutant A212CT250C.
  • FIG. 7 Overlay of analytical GFC traces at 280 nm of monomeric, HMW, and SHMW fractions of CRALBP after pooling and concentrating the corresponding fraction from the preparative GFC.
  • Panel A shows GFC traces of the wild-type CRALBP and panel B of the dicysteine mutant A212CT250C.
  • FIG. 8 Photostability half-lives (ti/2) of both redox states of the di-cysteine CRALBP mutant in complex with czs-retinal, respectively.
  • the inventive di-cysteine mutant A212C:T250C within CRALBP represents a redox switch that locks the visual pigment increasing its photostability 20-fold at 1000 lux.
  • FIG. 9 Photoisomerization of the oxidized mutant A212C:T250C as oxidized using 5mM oxidized glutathione.
  • A212CT250C : l l -cz.s-retinal) 5.988* 10' 5 S _1 . NO photoisomerization was detectable in the case of oxidized A212C:T250C:9- cz -retinal.
  • FIG. 10 Image of a 3-12% Native PAGE featuring individual fractions from the preparative GFC of CRALBP after loading with 9-cz.s-retinal.
  • Panel A shows the wild-type CRALBP. Description of lanes: M, Marker (InvitrogenTM NativeMarkTM); Pl and Pl .2 SHMW fractions (C4-E8); P2 HMW Fractions (E8); P4 monomeric fraction (F7).
  • Panel B shows the di-cysteine mutant A212C:T250C. Description of lanes: M, Marker (InvitrogenTM NativeMarkTM); Pl and Pl.2 SHMW fractions (5-8); P2 HMW Fractions (12-13); P4 monomeric fraction (26).
  • FIG. 11 Bar chart showing the average size, including error ( ⁇ SD), of different complex fractions of wild-type CRALBP and CRALBP di-cysteine mutant A212C:T250C after loading with 9-cz.s-retinal.
  • Panel A complex of monomeric wild-type CRALBP with 9-cz.s-retinal is 6.45 ⁇ 0.76 nm, dimeric complex 7.07 ⁇ 0.29 nm, HMW 12.89 ⁇ 0.89 nm and SHMW 21.43 ⁇ 7.07 nm respectively.
  • Panel B, Di-cysteine mutant A212C:T250C CRALBP with 9-cz.s-retinal monomeric complex is 6.50 ⁇ 1.50 nm, dimeric complex 8.72 ⁇ 2.41 nm, HMW 13.50 ⁇ 0.47 nm, and SHMW 28.28 ⁇ 2.13 nm respectively.
  • FIG. 12 Representative results for ex-vivo ERGs.
  • Panel A rod-driven a-waves from retina stimulated with 20ms, 505 nm LED flashes delivering 0.5 log unit steps of light intensity. Retinas were treated with monomeric and super high molecular weight (SHMW) CRALBP wild-type preparations.
  • SHMW monomeric and super high molecular weight
  • the CRALBP solution contained approximately 1.62 mM of 9-cz.s-retinal and was diluted to in 1.8 ml of L15 cell culture solution (13.6mg/ml, pH 7.4, Sigma) containing 1% BSA and suspended thoroughly. The final concentration of the retinoid was 162 pM.
  • An isolated RPE65- I- retina was incubated in a Petri dish with 2ml of diluted wilt-type CRALBP/9-cis-retinal solution in an oxygenated container for 4-4.5h in the dark.
  • Panel B rod-driven a- waves from retinas as described for panel B but treated with monomeric and SHMW CRALBP A212C:T250C mutant complexed to 9-cis-retinal. All error bars represent mean values ⁇ SEM using the independent two-tailed Student’s Z-test, with a significance threshold of P ⁇ 0.05.
  • FIG. 13 Representative results for in vivo ERGs of RPE65-/- mice treated with wild-type monomeric CRALBP/9-cis-retinal complexes. Averaged ERG responses of RPE65-/- mice injected into the vitreous of the eye. The injections were performed by hand using a Hamilton syringe under the microscope and infrared illumination. Control eyes were injected with the same volume of PBS as the treated eyes. Mice were kept all the time in the dark and allowed to recover. The animals returned after the anesthesia in their original cages with access to food and water. Recordings of intensity-response were carried out after 25-30 h (day 1) and 48-72 h (days 3-4). Panel A, Averaged ERG a-wave responses. Panel B, Averaged ERG b-wave responses. All error bars represent mean values ⁇ SEM using the independent two-tailed Student’s Z-test, with a significance threshold of P ⁇ 0.05.
  • FIG. 14 Representative results for in vivo ERGs of RPE65-/- mice treated with wild-type super high molecular weight (SHMW) CRALBP/9-cis-retinal complexes. Averaged ERG responses of RPE65-/- mice injected into the vitreous of the eye. The injections were performed by hand using a Hamilton syringe under the microscope and infrared illumination. Control eyes were injected with the same volume of PBS as the treated eyes. Mice were kept all the time in the dark and allowed to recover. The animals returned after the anesthesia in their original cages with access to food and water. Recordings of intensity-response were carried out after 25-30 h (day 1) and 48-72 h (days 3-4). Panel A, Averaged ERG a-wave responses. Panel B, Averaged ERG b-wave responses. All error bars represent mean values ⁇ SEM using the independent two-tailed Student’s Z-test, with a significance threshold of P ⁇ 0.05.
  • SHMW super high mo
  • FIG. 15 Representative results for in vivo ERGs of RPE65-/- mice treated with mutant A212C:T250C monomeric CRALBP/9-cis-retinal complexes. Averaged ERG responses of RPE65-/- mice injected into the vitreous of the eye. The injections were performed by hand using a Hamilton syringe under the microscope and infrared illumination. Control eyes were injected with the same volume of PBS as the treated eyes. Mice were kept all the time in the dark and allowed to recover. The animals returned after the anesthesia in their original cages with access to food and water. Recordings of intensity-response were carried out after 25-30 h (day 1) and 48-72 h (days 3-4). Panel A, Averaged ERG a-wave responses. Panel B, Averaged ERG b-wave responses. All error bars represent mean values ⁇ SEM using the independent two-tailed Student’s /-test, with a significance threshold of P ⁇ 0.05.
  • FIG. 16 Representative results for in vivo ERGs of RPE65-/- mice treated with mutant A212C:T250C super high molecular weight (SHMW) CRALBP/9-cis-retinal complexes. Averaged ERG responses of RPE65-/- mice injected into the vitreous of the eye. The injections were performed by hand using a Hamilton syringe under the microscope and infrared illumination. Control eyes were injected with the same volume of PBS as the treated eyes. Mice were kept all the time in the dark and allowed to recover. The animals returned after the anesthesia in their original cages with access to food and water. Recordings of intensityresponse were carried out after 25-30 h (day 1) and 48-72 h (days 3-4). Panel A, Averaged ERG a-wave responses. Panel B, Averaged ERG b-wave responses. All error bars represent mean values ⁇ SEM using the independent two-tailed Student’s /-test, with a significance threshold ofP ⁇ 0.05.
  • FIG. 17 Representative results for dark adaptation in vivo ERGs of RPE65-/- mice treated with wild-type monomeric and SHMW CRALBP/9-cis-retinal complexes. Dark adaptation ERGs were performed, and results were reported as sensitivity as a function of time.
  • Fig. 18 Representative results for dark adaptation in vivo ERGs of RPE65-/- mice treated with mutant A212C:T250C monomeric and SHMW CRALBP/9-cis-retinal complexes. Dark adaptation ERGs were performed, and results were reported as sensitivity as a function of time.
  • the terms "about” when referring to any numerical value are intended to mean a value of ⁇ 10% of the stated value. In a preferred embodiment, said “about” when referring to any numerical value are intended to mean a value of ⁇ 5% of the stated value. In another preferred embodiment, said “about” when referring to any numerical value are intended to mean a value of ⁇ 3% of the stated value.
  • CRALBP protein refers to a protein comprising or consisting of a wild-type CRALBP protein, or comprising or consisting of a CRALBP mutant protein, as defined herein.
  • Wild-type CRALBP protein refers to a cellular retinal binding protein (CRALBP) as occurred in nature for an animal, preferably a mammal, and further preferably for a human.
  • CRALBP retinal binding protein
  • wild-type CRALBP protein refers to human wild-type CRALBP protein of SEQ ID NO:3.
  • CRALBP mutant protein refers to a mutein of a wild-type CRALBP protein, preferably of human wild-type CRALBP protein of SEQ ID NO:3.
  • CRALBP mutant protein refers to a mutein of human wild-type CRALBP protein of SEQ ID NO: 3 having a sequence identity of at least 90% with SEQ ID NO:3.
  • mutant refers to a protein or polypeptide differing by one or more amino acids from a given reference (e.g. natural, wild-type, etc. protein or polypeptide, wherein such difference is caused by addition, substitution or deletion of at least one amino acid or a combination thereof.
  • Preferred embodiments comprise mutations derived from substitution of at least one amino acid, preferably derived from conservative substitution of at least one amino acid.
  • Conservative substitutions include isosteric substitutions, substitutions where the charged, polar, aromatic, aliphatic or hydrophobic nature of the amino acid is maintained. For example, substitution of a cysteine residue with a serine residue is a conservative substitution.
  • mutein refers to a mutein of a wild-type CRALBP protein having a sequence identity of at least 90 % with said wild-type CRALBP protein, or to a mutein of a wild-type CRALBP protein differing by at most 30, typically and preferably by at most 20 or 10 amino acids from said wild-type CRALBP protein.
  • mutein refers to a mutein of a wild-type CRALBP protein, preferably of SEQ ID NO:3, having a sequence identity of at least 90 %, 91%, 92%, 93%, 94, 95%, 96% with said wild-type CRALBP protein, preferably of SEQ ID NO:3, or to a mutein of a wild-type CRALBP protein, preferably of SEQ ID NO:3, differing by at most 30, typically and preferably by at most 20, or 10, 9, 8, 7, 6 amino acids from said wild-type CRALBP protein, preferably of SEQ ID NO:3.
  • Position corresponding to amino acid residues... The position on an amino acid sequence, which is corresponding to given residues of another amino acid sequence can be identified by sequence alignment, typically and preferably by using the BLASTP algorithm, most preferably using the standard settings. Typical and preferred standard settings are: expect threshold: 10; word size: 3; max matches in a query range: 0; matrix: BLOSUM62; gap costs: existence 11, extension 1; compositional adjustments: conditional compositional score matrix adjustment.
  • one cysteine of each pair of amino acid mutations by cysteines is a mutation of an amino acid within the amino acid residues corresponding to amino acids 204-229 of SEQ ID NO:3, wherein the other mutated amino acid by cysteine of said pair is a mutation of an amino acid within the amino acid residues corresponding to amino acids 244-261 of SEQ ID NO: 3.
  • SEQ ID NO: 3 refers to human wild-type CRALBP
  • the corresponding specific animal or mammal CRALBP positions are therefore corresponding to said human wild-type CRALBP.
  • able of forming a disulfide bond and “capable of forming a disulfide bond”, as interchangeably used herein and referring to pairs of cysteines being amino acid mutations as compared to the wild-type CRALBP protein, typically and preferably refer to the ability and capability, respectively, of the mutated cysteines to form disulfide bonds as typically and preferably determined in a manner as described in Example 3.
  • Sequence identity The sequence identity of two given amino acid sequences is determined based on an alignment of both sequences. Algorithms for the determination of sequence identity are available to the artisan. Preferably, the sequence identity of two amino acid sequences is determined using publicly available computer homology programs such as the “BLAST” program (http://blast.ncbi.nlm.nih. ov/Blast.c i) or the “CLUSTALW” (http ://www. enome. i p/tool s/ clustal w/), and hereby preferably by the “BLAST” program provided on the NCBI homepage at http://blast.ncbi.nlm.nih.gov/Blast.cgi, using the default settings provided therein.
  • amino acid exchange refers to the exchange of a given amino acid residue in an amino acid sequence by any other amino acid residue having a different chemical structure, preferably by another proteinogenic amino acid residue. Thus, in contrast to insertion or deletion of an amino acid, the amino acid exchange does not change the total number of amino acids of said amino acid sequence. In case of an amino acid exchange within the present invention and referring to typically and preferably non-functional amino acid substitutions, conservative amino acid substitutions are preferred.
  • Conservative amino acid substitutions include, and typically and preferably consist of isosteric substitutions, substitutions where the charged, polar, aromatic, aliphatic or hydrophobic nature of the amino acid is maintained.
  • Typical conservative substitutions are substitutions between amino acids within one of the following groups: Gly, Ala; Vai, He, Leu; Asp, Glu; Asn, Gin; Ser, Thr, Cys; Lys, Arg; and Phe and Tyr.
  • polypeptide refers to a polymer composed of amino acid monomers which are linearly linked by amide bonds (also known as peptide bonds). It indicates a molecular chain of amino acids and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides and proteins are included within the definition of polypeptide.
  • polypeptide should also refer, typically and preferably to a polypeptide as defined before and encompassing modifications such as post- translational modifications, including but not limited to glycosylations.
  • polypeptide as used herein should refer to a polypeptide as defined before and not encompassing modifications such as post-translational modifications such as glycosylations.
  • modifications such as said glycosylations can occur even in vivo thereafter, for example, by bacteria.
  • a cognate ligand of CRALBP refers to a molecule that binds the binding pocket of wild-type CRALBP protein, preferably human wild-type CRALBP protein of SEQ ID NO:3, with at least nanomolar affinity of typically and preferably 1-200 nM, further preferably of 1-100 nM, further typically and preferably with an affinity of 6-80 nM (wherein said affinity is typically and preferably determined as described in Golovleva I., et al., 2003, J. Biol. Chem. 278(14)), and which molecule is typically and preferably functionally associated with the wild-type CRALBP protein.
  • Functionally associated refers to the physiological function of the wild-type CRALBP protein, preferably of human wild-type CRALBP protein of SEQ ID NO:3.
  • cA-retinoid refers to a natural or synthetic molecule, typically and preferably a Vitamin A derivative, comprising a cyclohexen or a phenyl moiety, typically and preferably substituted by one or more methyl and/or methoxy substituents, which cyclohexen or phenyl moiety is (further) substituted by a Ce-Cu linear or branched alkenyl group having at its terminal carbon atom (terminal carbon atom in relation to its attachment to the cyclohexen or phenyl moiety) an alcohol, aldehyde, carboxy or an ester functionality, wherein said linear or branched alkenyl group have at least one carbon-carbon double bond, typically and preferably one or more, most preferably four carbon-carbon double bonds, wherein at least one of said carbon-carbon double bond is in the cis configuration.
  • Said cis- retinoid includes retinol, retinaldehyde, and tretinoin, isotretinoin, alitretinoin, etretinate, acitretin as well as its esters, of which retinol and retinaldehyde are preferred.
  • C/.s-retinoids have been described (Mukherjee S et al., 2006, Clin Interv Aging. l(4):327-48; Kiser PD et al., 2014, Chem. Rev. 114: 194-232).
  • complex refers to (i) a 1 : 1 monomeric complex of said CRALBP protein and said cognate ligand of CRALBP, wherein said cognate ligand of CRALBP binds said CRALBP protein, typically and preferably with at least nanomolar affinity of 1-200 nM, further preferably of 1-100 nM (wherein said affinity is typically and preferably determined as described in Golovleva I., et al., 2003, J. Biol. Chem.
  • said complex comprises, preferably consists of, a wild-type CRALBP protein and a cognate ligand of CRALBP, and hereby refers to (i) a 1 : 1 monomeric complex of said wild-type CRALBP protein and said cognate ligand of CRALBP, wherein said cognate ligand of CRALBP binds said wild-type CRALBP protein, typically and preferably with at least nanomolar affinity of 1-200 nM, further preferably of 1-100 nM (wherein said affinity is typically and preferably determined as described in Golovleva I., et al., 2003, J. Biol. Chem.
  • said complex comprises, preferably consists of, a CRALBP mutant protein and a cognate ligand of CRALBP, and hereby refers to (i) a 1 : 1 monomeric complex of said CRALBP mutant protein and said cognate ligand of CRALBP, wherein said cognate ligand of CRALBP binds said CRALBP mutant protein, typically and preferably with at least nanomolar affinity of 1-200 nM, further preferably of 1- 100 nM (wherein said affinity is typically and preferably determined as described in Golovleva I., et al., 2003, J. Biol. Chem.
  • the number of said cognate ligands within said dimeric and/or oligomeric complexes of said CRALBP protein, wild-type CRALBP protein or CRALBP mutant protein and said cognate ligand of CRALBP are equal to the number of said CRALBP proteins, wild-type CRALBP proteins or CRALBP mutant proteins.
  • retina disease or disorder refers to a disease or disorder that cause damage to any part of the retina.
  • an inherited retinal disease or disorder refers to a retinal disease or disorder that can cause severe vision loss or even blindness typically by altering the structure and function of the retina, and is caused by at least one gene that is not working as it should.
  • An inherited retinal disease or disorder can affect individuals of all ages, can progress at different rates, and are rare. However, many inherited retinal diseases or disorders are degenerative, in particular with respect to retina, meaning that the symptoms of the disease or disorder will get worse over time.
  • maintaining or improving visual function shall be understood as the maintenance of substantially the same level or an improvement in the level of vision as assessed by one or more test of visual function, when the vision in a treated eye is compared before and after the methods of the invention have been performed.
  • the inventive treatment of the endogenous retinoid deficiencies and/or retinal diseases, disorders and dystrophies including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age- related macular degeneration (AMD), preferably dry AMD, Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB)
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • AMD age- related macular degeneration
  • CSNB retinitis punctata albesciens
  • CSNB cone stationary night blindness
  • visual function tests that might be carried out by the skilled person include best corrected visual acuity, visual field testing, micro perimetry, colour vision, dark adaptometry, electroretinography and cone flicker fusion tests.
  • said maintaining or improving visual function refers to the maintenance of substantially the same level or an improvement in the level of vision as assessed by one or more test of visual function, when the vision in a treated eye is compared before and after the methods of the invention have been performed, and wherein said one or more test of visual function comprises, preferably consists of, ERG measurements as effected and described in Examples 12 to 14, preferably as effected and described in Example 13 and 14.
  • visual function is improved, preferably substantially restored, or maintained in the treated eye.
  • Visual function for example as determined by a test of visual function as described herein, may, for example, be improved, preferably restored to about the same level in an affected eye as existed before the onset of the endogenous retinoid deficiencies, the retinoid deficiencies of the retina, and/or retinal diseases, disorders and dystrophies including RP, LCA, AMD, preferably dry AMD, STGD, COD, CRD, RPA, fundus albipunctatus and CSNB.
  • visual function is improved as compared to a level in an affected eye as existed before the onset of the endogenous retinoid deficiencies and/or retinal diseases, disorders and dystrophies including RP, LCA, AMD, preferably dry AMD, STGD, COD, CRD, RPA, fundus albipunctatus and CSNB and as compared before the methods of the invention have been performed.
  • visual function is maintained at about the same level in a healthy animal or subject at risk of developing an endogenous retinoid deficiency and/or a retinal disease, disorder or dystrophy including RP, LCA, AMD, preferably dry AMD, STGD, COD, CRD, RPA, fundus albipunctatus and CSNB, or in a subject or animal already suffering from an endogenous retinoid deficiency and/or a retinal disease, disorder or dystrophy including RP, LCA, AMD, preferably dry AMD, STGD, COD, CRD, RPA, fundus albipunctatus and CSNB.
  • subject refers to an animal, preferably to a human. In a very preferred embodiment said subject is a human.
  • animal refers to an animal (e.g., a non human animal), a vertebrate animal, a mammal, a rodent (e.g., a guinea pig, a hamster), a canine (e.g., a dog), a feline (e.g., a cat), a porcine (e.g., a pig), an equine (e.g., a horse), a primate, or a human.
  • said animal is a mammal.
  • said animal is a human or a non-human mammal preferably selected from a dog, a cat, and a horse.
  • said animal is a human.
  • treatment of a disorder or disease as used herein (e.g., “treatment” of a retinal disease) is well known in the art.
  • Treatment of a disorder or disease implies that a disorder or disease is suspected or has been diagnosed in an animal, subject or patient.
  • An animal or subject suspected of suffering from a disorder or disease typically shows specific clinical and/or pathological symptoms which a skilled person can easily attribute to a specific pathological condition (i.e., diagnose a disorder or disease).
  • the "treatment" of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease (e.g., no deterioration of symptoms) or a delay in the progression of the disorder or disease (in case the halt in progression is of a transient nature only).
  • the “treatment” of a disorder or disease may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the animal, subject or patient suffering from the disorder or disease.
  • the "treatment” of a disorder or disease may also refer to an amelioration of the disorder or disease, which may, e.g., lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease.
  • Such a partial or complete response may be followed by a relapse. It is to be understood that an animal or subject may experience a broad range of responses to a treatment.
  • the treatment of a disorder or disease may, inter alia, comprise curative treatment (preferably leading to a complete response and/or eventually to healing of the disorder or disease) and palliative treatment (including symptomatic relief).
  • the "amelioration" of a disorder or disease may, for example, lead to a halt in the progression of the disorder or disease or a delay in the progression of the disorder or disease.
  • prevention refers to a prophylactic treatment.
  • the treatment with the compositions for use in the methods of the present invention may be assessed by different measures of visual and ocular function and structure, as referred herein and including, among others, best corrected visual acuity (BCVA), retinal sensitivity to light as measured by perimetry or microperimetry in the dark and light- adapted states, full-field, multi-focal, focal or pattern elecroretinography ERG, contrast sensitivity, reading speed, color vision, clinical biomicroscopic examination, fundus photography, optical coherence tomography (OCT), fundus auto- fluorescence (FAF), infrared and multicolor imaging, fluorescein or ICG angiography, and additional means used to evaluate visual function and ocular structure.
  • BCVA best corrected visual acuity
  • OCT optical coherence tomography
  • FAF fundus auto- fluorescence
  • ICG angiography additional means used to evaluate visual function and ocular structure.
  • the treatment or prevention with the compositions for use in the methods of the present invention, as described herein, may result in protection of the photoreceptor cells, such as the cone cells, from degeneration.
  • the treatment protects both cone and rod cells from degeneration.
  • Numbers of rods and cones can be estimated by the skilled person in the clinic using techniques such as adaptive optics, autofluorescence and optical coherence tomography (OCT) scans.
  • the term “effective amount”, as used herein, refers to an amount necessary or sufficient to realize a desired biologic effect.
  • the term “effective amount” refers to an amount of an inventive composition or an inventive pharmaceutical composition that (i) treats the particular disease or disorder, and/or (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or disorder, and/or (iii) or (iii) prevents or delays the onset of one or more symptoms of the particular disease or disorder, described herein.
  • the effective amount of the inventive compositions is capable of maintaining, restoring or improving visual function of the animal or subject, preferably human, and/or preventing or reducing chromphore depletion in an animal or subject, preferably human, and/or reducing clinical symptoms.
  • the "effective amount" may vary depending on the disease and its severity and the age, weight, medical history, susceptibility, and preexisting conditions, of the animal or subject, preferably human to be treated.
  • the present invention relates to the use of CRALBP based compositions and complexes for the treatment of multiple groups of diseases and disorders, preferably retinal diseases and disorders that are, in particular caused by endogenous retinoid deficiency and/or by retinoid deficiency of the retina.
  • diseases and disorders preferably retinal diseases and disorders that are, in particular caused by endogenous retinoid deficiency and/or by retinoid deficiency of the retina.
  • CRALBP has dual function in that it sequesters the cz.s-retinoid, in particular the l l -cz.s retinal or the 9-cis retinal, and prevents it from premature photoisomerization as well as preventing the cellular context from aldehyde toxicity.
  • CRALBP represents in the vision cycle the most downstream protein component, and has high affinity for the bound cz.s-retinoid, in particular the l l -cz.s retinal or the 9-cis retinal, and chaperones the reloading process of the opsin receptor molecules within the rod and cone photoreceptor cells.
  • RPE65-/- mouse model The collection of in vitro and in vivo data using a chromophore deficient RPE65-/- mouse model yielded consistent data of rod receptor recovery and increased bleaching resistance.
  • the RPE65-/- mouse model was chosen because the enzyme termed RPE65 catalyses the conversion of the light-insensitive all-/zzzzz.s retinyl ester to light-sensitive l l -cz.s retinol for promoting cz.s-retinoid regeneration within the pigment epithelium of the mouse retina (RPE) (Moiseyev, G., et al., 2005, Proc. Nat. Acad. Sci. 102: 12413-12418).
  • the abrogation of the enzyme’ s activity in the RPE65-/- mouse is characterized by the virtual absence of 11 -cis retinal chromophore regeneration and related absence of light-sensitive rod photoreceptors i.e. a hallmark of impaired vision (Maeda, T., et al., 2009, Invest Ophthalmol Vis Sci. 50(9):4368- 78).
  • In vitro and in vivo restoration of light-sensitive rod photoreceptors in such mouse model is a strong indicator for the high biological potency of the treatment.
  • the provided inventive methods and uses of the described drugs are able to produce meaningful improvement of vision in a subject having an endogenous retinoid deficiency and/or a retinoid deficiency of the retina.
  • the treatment is also novel in that it is believed to be not targeting a specific gene defect but instead is meant to circumvent all components of the visual cycle to directly replenish in vitro and in vivo chromophore depleted rod and cone photoreceptors with fresh cz.s-retinoid, in particular cz -retinal.
  • This mechanism thus represents a so far unknown shunt and may fulfil the requirements for a broader, i.e. nontargeted, therapeutic approach.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, preferably of said human, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cz.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein preferably said disease or disorder is a retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cv.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a retinal disease or disorder of an animal, preferably of a human, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a c/.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, preferably of said human, and wherein said disease or disorder is a retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a c/.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is an inherited retinal disease or disorder, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cv.s-retinoid.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is an inherited retinal disease or disorder associated with a retinoid deficiency of the retina of said animal, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cv.s-retinoid.
  • said disease or disorder is a retinal disease or disorder.
  • said disease or disorder is an inherited retinal disease or disorder.
  • said disease or disorder is an inherited retinal disease or disorder associated with a retinoid deficiency of the retina of said animal, preferably of said human.
  • said disease or disorder is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said disease or disorder is RP.
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • AMD age-related macular degeneration
  • STGD Stargardt disease
  • COD cone dystrophy
  • CCD cone-rod dystrophy
  • RPA retinitis punctata albesciens
  • CSNB cone stationary night blindness
  • said retinal disease or disorder is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said disease or disorder is RP.
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • AMD age-related macular degeneration
  • STGD Stargardt disease
  • COD cone dystrophy
  • CCD cone-rod dystrophy
  • RPA retinitis punctata albesciens
  • CSNB cone stationary night blindness
  • said inherited retinal disease or disorder is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said disease or disorder is RP.
  • RP retinitis pigmentosa
  • LCA Leber congenital amaurosis
  • AMD age-related macular degeneration
  • STGD Stargardt disease
  • COD cone dystrophy
  • CCD cone-rod dystrophy
  • RPA retinitis punctata albesciens
  • CSNB cone stationary night blindness
  • the disease or disorder is retinitis pigmentosa (RP). In a preferred embodiment, the disease or disorder is moderate to severe RP. In a preferred embodiment, the disease or disorder is mild RP. In a preferred embodiment, the disease or disorder is early onset or juvenile RP. In a preferred embodiment, the disease or disorder is Leber congenital amaurosis (LCA). In a preferred embodiment, the disease or disorder is age- related macular degeneration (AMD), preferably dry AMD. In a preferred embodiment, the disease or disorder is Stargardt disease (STGD). In a preferred embodiment, the disease or disorder is cone dystrophy (COD). In a preferred embodiment, the disease or disorder is conerod dystrophy (CRD).
  • RP retinitis pigmentosa
  • the disease or disorder is moderate to severe RP. In a preferred embodiment, the disease or disorder is mild RP. In a preferred embodiment, the disease or disorder is early onset or juvenile RP. In a preferred embodiment, the disease or disorder is Leber congenital am
  • the disease or disorder is retinitis punctata albesciens (RPA).
  • the disease or disorder is fundus albipunctatus.
  • the disease or disorder is cone stationary night blindness (CSNB).
  • the disease or disorder is a RPE65 gene mutation.
  • the disease or disorder is a LRAT gene mutation.
  • the retinal disease or disorder is retinitis pigmentosa (RP).
  • the retinal disease or disorder is moderate to severe RP.
  • the retinal disease or disorder is mild RP.
  • the retinal disease or disorder is early onset or juvenile RP.
  • the retinal disease or disorder is Leber congenital amaurosis (LCA).
  • the retinal disease or disorder is age-related macular degeneration (AMD), preferably dry AMD.
  • AMD age-related macular degeneration
  • the retinal disease or disorder is Stargardt disease (STGD).
  • the retinal disease or disorder is cone dystrophy (COD).
  • the retinal disease or disorder is cone-rod dystrophy (CRD).
  • the retinal disease or disorder is retinitis punctata albesciens (RPA).
  • the retinal disease or disorder is fundus albipunctatus.
  • the retinal disease or disorder is cone stationary night blindness (CSNB).
  • the retinal disease or disorder is a RPE65 gene mutation.
  • the retinal disease or disorder is a LRAT gene mutation.
  • the inherited retinal disease or disorder is retinitis pigmentosa (RP).
  • the inherited retinal disease or disorder is moderate to severe RP.
  • the inherited retinal disease or disorder is mild RP.
  • the inherited retinal disease or disorder is early onset or juvenile RP.
  • the inherited retinal disease or disorder is Leber congenital amaurosis (LCA).
  • the inherited retinal disease or disorder is age-related macular degeneration (AMD), preferably dry AMD.
  • the inherited retinal disease or disorder is Stargardt disease (STGD).
  • the inherited retinal disease or disorder is cone dystrophy (COD).
  • the inherited retinal disease or disorder is cone-rod dystrophy (CRD).
  • the inherited retinal disease or disorder is retinitis punctata albesciens (RPA).
  • the inherited retinal disease or disorder is fundus albipunctatus.
  • the inherited retinal disease or disorder is cone stationary night blindness (CSNB).
  • the inherited retinal disease or disorder is a RPE65 gene mutation.
  • the inherited retinal disease or disorder is a LRAT gene mutation.
  • the present invention provides a composition for use in a method of maintaining or improving visual function in an animal, preferably in a human, having an endogenous retinoid deficiency, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of maintaining or improving visual function in an animal, preferably in a human, having a retinoid deficiency of the retina, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of reducing or preventing chromphore depletion in an animal, preferably in a human, having an endogenous retinoid deficiency, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of reducing or preventing chromphore depletion in an animal, preferably in a human, having a retinoid deficiency of the retina, wherein said method comprises administering, preferably by way of intravitreal administration, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP protein; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • said endogenous retinoid deficiency is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), preferably dry AMD, Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation wherein preferably said endogenous retinoid deficiency is RP.
  • said retinoid deficiency of the retina is selected from retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), preferably dry AMD, Stargardt disease (STGD), cone dystrophy (COD), cone-rod dystrophy (CRD), retinitis punctata albesciens (RPA), fundus albipunctatus and cone stationary night blindness (CSNB), a RPE65 gene mutation and a LRAT gene mutation, wherein preferably said endogenous retinoid deficiency is RP.
  • said animal is a human.
  • the endogenous retinoid deficiency is retinitis pigmentosa (RP). In a preferred embodiment, the endogenous retinoid deficiency is moderate to severe RP. In a preferred embodiment, the endogenous retinoid deficiency is mild RP. In a preferred embodiment, the endogenous retinoid deficiency is early onset or juvenile RP. In a preferred embodiment, the endogenous retinoid deficiency is Leber congenital amaurosis (LCA). In a preferred embodiment, the endogenous retinoid deficiency is age-related macular degeneration (AMD), preferably dry AMD.
  • AMD age-related macular degeneration
  • the endogenous retinoid deficiency is Stargardt disease (STGD).
  • the endogenous retinoid deficiency is cone dystrophy (COD).
  • the endogenous retinoid deficiency is conerod dystrophy (CRD).
  • the endogenous retinoid deficiency is retinitis punctata albesciens (RPA).
  • the endogenous retinoid deficiency is fundus albipunctatus.
  • the endogenous retinoid deficiency is cone stationary night blindness (CSNB).
  • the endogenous retinoid deficiency is a RPE65 gene mutation.
  • the endogenous retinoid deficiency is a LRAT gene mutation.
  • the retinoid deficiency of the retina is retinitis pigmentosa (RP).
  • RP retinitis pigmentosa
  • the retinoid deficiency of the retina is moderate to severe RP.
  • the retinoid deficiency of the retina is mild RP.
  • the retinoid deficiency of the retina is early onset or juvenile RP.
  • the retinoid deficiency of the retina is Leber congenital amaurosis (LCA).
  • the retinoid deficiency of the retina is age-related macular degeneration (AMD), preferably dry AMD.
  • AMD age-related macular degeneration
  • the retinoid deficiency of the retina is Stargardt disease (STGD).
  • the retinoid deficiency of the retina is cone dystrophy (COD).
  • the retinoid deficiency of the retina is conerod dystrophy (CRD).
  • the retinoid deficiency of the retina is retinitis punctata albesciens (RPA).
  • the retinoid deficiency of the retina is fundus albipunctatus.
  • the retinoid deficiency of the retina is cone stationary night blindness (CSNB).
  • the retinoid deficiency of the retina is a RPE65 gene mutation.
  • the retinoid deficiency of the retina is a LRAT gene mutation.
  • the animal preferably the human, has retinitis pigmentosa (RP).
  • RP retinitis pigmentosa
  • the animal, preferably the human has moderate to severe RP.
  • the animal, preferably the human has mild RP.
  • the animal, preferably the human has early onset or juvenile RP.
  • the animal, preferably the human has Leber congenital amaurosis (LCA).
  • the animal, preferably the human has age-related macular degeneration (AMD), preferably dry AMD.
  • the animal, preferably the human has Stargardt disease (STGD).
  • STGD Stargardt disease
  • the animal preferably the human, has cone dystrophy (COD). In a preferred embodiment, the animal, preferably the human, has cone-rod dystrophy (CRD). In a preferred embodiment, the animal, preferably the human, has retinitis punctata albesciens (RPA). In a preferred embodiment, the animal, preferably the human, has fundus albipunctatus. In a preferred embodiment, the animal, preferably the human, has cone stationary night blindness (CSNB). In a preferred embodiment, the animal, preferably the human, has a RPE65 gene mutation. In a preferred embodiment, the animal, preferably the human, has a LRAT gene mutation.
  • said composition is administered to the eye of said animal, preferably of said human, by subretinal, direct retinal or intravitreal injection, wherein preferably said composition is administered to the eye of said animal, preferably said human, by intravitreal injection.
  • the skilled person will be familiar with and well able to carry out individual subretinal, direct retinal or intravitreal injections.
  • Subretinal injections are injections into the subretinal space, i.e. underneath the neurosensory retina.
  • Intravitreal is a route of administration of a drug, or other substance, in which the substance is delivered into the vitreous humor of the eye, i.e. administration directly into the vitreous chamber.
  • the visual function of said animal, preferably of said human is substantially restored or maintained in the treated eye.
  • said animal is a human.
  • said CRALBP protein comprises a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said CRALBP protein comprises a wild-type CRALBP protein. In a preferred embodiment, said CRALBP protein comprises a CRALBP mutant protein. In a preferred embodiment, said CRALBP protein consists of a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said CRALBP protein consists of a wild-type CRALBP protein. In a preferred embodiment, said CRALBP protein consists of a CRALBP mutant protein. In a preferred embodiment, said CRALBP protein is a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said CRALBP protein is a wild-type CRALBP protein. In a preferred embodiment, said CRALBP protein is a CRALBP mutant protein.
  • said CRALBP protein comprises a wild-type CRALBP protein.
  • said CRALBP protein comprises a wild-type CRALBP protein, and wherein said wild-type CRALBP protein comprises human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a wildtype CRALBP protein, and wherein said wild-type CRALBP protein consists of human wildtype CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a wild-type CRALBP protein, and wherein said wild-type CRALBP protein is the human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a wild-type CRALBP protein, and wherein said CRALBP protein comprises human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a wild-type CRALBP protein, and wherein said CRALBP protein consists of human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein consists of a wild-type CRALBP protein, and wherein said CRALBP protein consists of human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a wild-type CRALBP protein, and wherein said CRALBP protein is the human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein consists of a wild-type CRALBP protein, and wherein said CRALBP protein is the human wild-type CRALBP protein of SEQ ID NO:3.
  • said CRALBP protein comprises a CRALBP mutant protein, wherein said CRALBP mutant protein comprises a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond.
  • said CRALBP protein comprises a CRALBP mutant protein, wherein said CRALBP mutant protein consists of a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond.
  • said CRALBP protein comprises a CRALBP mutant protein, wherein said CRALBP protein comprises a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond.
  • said CRALBP protein comprises a CRALBP mutant protein, wherein said CRALBP protein consists of a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond.
  • said CRALBP protein consists of a CRALBP mutant protein, wherein said CRALBP protein consists of a mutein of a wild-type CRALBP protein, wherein said mutein consists of at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond.
  • the present invention provides a composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, wherein said method comprises administering, preferably by intravitreal injection, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein is a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a c/.s-retinoid.
  • the present invention provides a complex for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, wherein said method comprises administering, preferably by intravitreal injection, said complex to said animal, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein is a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond; and (b) a cognate ligand of CRALBP, wherein preferably said cognate ligand is a cisretinoid.
  • the present invention provides a composition for use in a method of preventing or treating a retinal disease or disorder of an animal, preferably of a human, wherein said method comprises administering, preferably by intravitreal injection, said composition to said animal, wherein said composition comprises, preferably consists of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein is a mutein of a wild-type CRALBP protein, wherein said mutein comprises at least one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, wherein each of said pair of cysteines is able of forming, preferably forms, a disulfide bond, and wherein one cysteine of each pair of amino acid mutations by cysteines is a mutation of an amino acid within the amino acid residues corresponding to amino acids 204-229 of SEQ ID NO:3, wherein the other mutated amino acid by cysteine of said pair is a mutation of an amino acid within
  • said CRALBP mutant protein has an amino acid sequence selected from group consisting of SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, and wherein preferably said CRALBP mutant protein has an amino acid sequence selected from SEQ ID NO: 11 and SEQ ID NO: 24, and wherein further preferably said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 11.
  • the present invention provides for a pharmaceutical composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, wherein said method comprises administering, preferably by intravitreal injection, said composition to said animal, wherein said composition comprises, preferably consists of, wherein said pharmaceutical composition comprises (a) the composition of the present invention; and (b) a pharmaceutically acceptable carrier.
  • the present invention provides for a pharmaceutical composition for use in a method of preventing or treating a disease or disorder of an animal, preferably of a human, wherein said disease or disorder is caused by an endogenous retinoid deficiency of said animal, wherein said method comprises administering, preferably by intravitreal injection, said composition to said animal, wherein said composition comprises, preferably consists of, wherein said pharmaceutical composition comprises (a) the complex of the present invention; and (b) a pharmaceutically acceptable carrier.
  • said cognate ligand preferably said cz.s-retinoid, is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11-cz -retinal; (iv) 11-cz -retinol; (v) 11, 13-di-cz.s- retinal; (vi) 11, 13-di-cz.s-retinol; (vii) 9, 13-di-cz.s-retinal; and (viii) 9, 13-di-cz.s-retinol.
  • said cognate ligand preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11-cz -retinal; (iv) 11-cz -retinol; (v) 9,13-di-cz.s-retinal; and (vi) 9,13-di-c/.s-retinol .
  • said cognate ligand, preferably said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 1 l-czs-retinal; and (iii) 9, 13-di-cv.s-retinal; and (vi) 9,13-di-cv.s-retinol.
  • said cognate ligand, preferably said cv.s-retinoid is selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal.
  • said cognate ligand, preferably said cv.s-retinoid is 9- cz -retinal. In a further preferred embodiment, said cognate ligand, preferably said cv.s-retinoid is 9-cv.s-retinol. In a further preferred embodiment, said cognate ligand, preferably said cisretinoid is l l-czs-retinal. In a further preferred embodiment, said cognate ligand, preferably said cv.s-retinoid is 11-czs-retinol.
  • said cognate ligand, preferably said cv.s-retinoid is 11,13-di-cz -retinal. In a further preferred embodiment, said cognate ligand, preferably said cv.s-retinoid is 11,13-di-cz -retinol. In a further preferred embodiment, said cognate ligand, preferably said cv.s-retinoid is 9,13-di-cv.s-retinal. In a further preferred embodiment, said cognate ligand, preferably said cv.s-retinoid is 9,13-di-cv.s-retinol.
  • said mutein of a wild-type CRALBP protein has a sequence identity of at least 90 % with said wild-type CRALBP protein, preferably of at least 95%, further preferably of at least 96%, again further preferably at least 97%, again further preferably at least 98%, and again more preferably of at least 99%.
  • said mutein of a wild-type CRALBP protein has a sequence identity of at least 95% with said wild-type CRALBP protein.
  • said mutein of a wild-type CRALBP protein has a sequence identity of at least 96% with said wild-type CRALBP protein.
  • said mutein of a wild-type CRALBP protein has a sequence identity of at least 97% with said wild-type CRALBP protein. In a further preferred embodiment said mutein of a wild-type CRALBP protein has a sequence identity of at least 98% with said wild-type CRALBP protein. In a further preferred embodiment said mutein of a wild-type CRALBP protein has a sequence identity of at least 99% with said wildtype CRALBP protein.
  • said mutein of a wild-type CRALBP protein differs by at most 30 amino acids from said wild-type CRALBP protein. In a further preferred embodiment, said mutein of a wild-type CRALBP protein differs by at most 20 amino acids from said wild-type CRALBP protein. In again another preferred embodiment, said mutein of a wild-type CRALBP protein differs by at most 10 amino acids from said wild-type CRALBP protein. In a further preferred embodiment said mutein of a wild-type CRALBP protein differs by 10, 9, 8, 7, 6, 5, 4, 3, 2 amino acids from said wild-type CRALBP protein.
  • said mutein of a wild-type CRALBP protein differs by at most 8 amino acids from said wild-type CRALBP protein. In a further preferred embodiment said mutein of a wild-type CRALBP protein differs by at most 6, 4 or 2 amino acids from said wild-type CRALBP protein.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence having a sequence identity of at least 90% with said wild-type CRALBP protein, preferably a sequence identity of at least 90% with of SEQ ID NO: 3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence having a sequence identity of at least 93% with said wild-type CRALBP protein, preferably a sequence identity of at least 93% with of SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence having a sequence identity of at least 96% with said wild-type CRALBP protein, preferably a sequence identity of at least 96% with of SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence having a sequence identity of at least 98% with said wild-type CRALBP protein, preferably a sequence identity of at least 98% with of SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence having a sequence identity of at least 99% with said wild-type CRALBP protein, preferably a sequence identity of at least 99% with of SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 15 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 10 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3. In a preferred embodiment, said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 8 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3. In a preferred embodiment, said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 6 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3.
  • said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 5 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3. In a preferred embodiment, said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 4 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3. In a preferred embodiment, said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 3 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3. In a preferred embodiment, said mutein of a wild-type CRALBP protein has an amino acid sequence differing by at most 2 amino acids from said wild-type CRALBP protein, preferably from said SEQ ID NO:3.
  • said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 90% with a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 90% with SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 93% with a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 93% with SEQ ID NO:3.
  • said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 96% with a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 96% with SEQ ID NO: 3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 98% with a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 98% with SEQ ID NO: 3.
  • said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 99% with a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence having a sequence identity of at least 99% with SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 15, 12, 10, 8 or 6 amino acids from a wild-type CRALBP protein. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 15 amino acids from SEQ ID NO:3.
  • said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 12 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 10 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 8 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 6 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 5 amino acids from SEQ ID NO:3.
  • said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 4 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 3 amino acids from SEQ ID NO:3. In a preferred embodiment, said CRALBP mutant protein comprises, or consists of, an amino acid sequence differing by at most 2 amino acids from SEQ ID NO:3.
  • one cysteine of each pair of amino acid mutations by cysteines is a mutation of an amino acid within the amino acid residues corresponding to amino acids 204-229 of SEQ ID NO:3, wherein the other mutated amino acid by cysteine of said pair is a mutation of an amino acid within the amino acid residues corresponding to amino acids 244-261 of SEQ ID NO:3.
  • said mutein comprises one, two, three or four pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein preferably said mutein comprises one or two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein.
  • each of said pair of cysteines forms a disulfide bond.
  • said mutein comprises one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein. In another preferred embodiment, said mutein comprises two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein. In a further preferred embodiment, said mutein comprises three pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein. In a further preferred embodiment, each of said pair of cysteines forms a disulfide bond.
  • said pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is selected from
  • said pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3.
  • said pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 217 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 253 of SEQ ID NO:3.
  • said pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 220 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 254 of SEQ ID NO:3.
  • said pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 224 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 257 of SEQ ID NO:3.
  • said mutein comprises one or two or three pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is selected from
  • (x) a first pair of amino acid mutations by cysteines, a second pair of amino acid mutations by cysteines, and a third pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3, said second pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 220 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 254 of SEQ ID NO:3, and said third pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 224 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 257 of SEQ ID NO:3.
  • said mutein comprises one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3.
  • said mutein comprises one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 217 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 253 of SEQ ID NO:3.
  • said mutein comprises one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said wild-type CRALBP protein is a mutation of an amino acid corresponding to amino acid 220 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 254 of SEQ ID NO:3.
  • said mutein comprises two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 220 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 254 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 224 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 257 of SEQ ID NO:3.
  • said mutein comprises two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 224 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 257 of SEQ ID NO:3.
  • said mutein comprises two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 217 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 253 of SEQ ID NO:3.
  • said mutein comprises three pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein, and wherein said three pairs of amino acid mutations by cysteines as compared to said wild-type CRALBP protein are a first pair of amino acid mutations by cysteines, a second pair of amino acid mutations by cysteines, and a third pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 212 of SEQ ID NO:3 and a mutation of an amino acid corresponding to amino acid 250 of SEQ ID NO:3, said second pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 220 of SEQ ID NO: 3 and a mutation of an amino acid corresponding to amino acid 254 of SEQ ID NO:3, and said third pair of amino acid mutations by cysteines is a mutation of an amino acid corresponding to amino acid 224 of SEQ ID NO:3
  • At least one of said pair of cysteines forms a disulfide bond. In another preferred embodiment, each of said pair of cysteines forms a disulfide bond.
  • said wild-type CRALBP protein is the human wild-type CRALBP protein of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human wild-type CRALBP protein of SEQ ID NO:3, and said pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is selected from
  • said mutein of said human wild-type CRALBP protein has a sequence identity of at least 90 % with said human wild-type CRALBP protein, preferably of at least 95%, further preferably of at least 96%, again further preferably at least 97%, again further preferably at least 98%, and again more preferably of at least 99%.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein has a sequence identity of at least 95% with said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein has a sequence identity of at least 96% with said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein has a sequence identity of at least 97% with said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein has a sequence identity of at least 98% with said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wildtype CRALBP protein has a sequence identity of at least 99% with said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by at most 30 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by at most 20 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by at most 10 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by 10, 9, 8, 7, 6, 5, 4, 3, 2 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by at most 8 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein of said human wild-type CRALBP protein differs by at most 6, 4 or 2 amino acids from said human wild-type CRALBP protein.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, said pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 217 of SEQ ID NO:3 and a mutation of amino acid 253 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 220 of SEQ ID NO: 3 and a mutation of amino acid 254 of SEQ ID NO: 3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 224 of SEQ ID NO:3 and a mutation of amino acid 257 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises one or two or three pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said human wildtype CRALBP protein is selected from
  • (x) a first pair of amino acid mutations by cysteines, a second pair of amino acid mutations by cysteines, and a third pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3, said second pair of amino acid mutations by cysteines is a mutation of amino acid 220 of SEQ ID NO:3 and a mutation of amino acid 254 of SEQ ID NO:3, and said third pair of amino acid mutations by cysteines is a mutation of amino acid 224 of SEQ ID NO:3 and a mutation of amino acid 257 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 217 of SEQ ID NO:3 and a mutation of amino acid 253 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said one pair of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein is a mutation of amino acid 220 of SEQ ID NO:3 and a mutation of amino acid 254 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of amino acid 220 of SEQ ID NO:3 and a mutation of amino acid 254 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of amino acid 224 of SEQ ID NO:3 and a mutation of amino acid 257 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of amino acid 224 of SEQ ID NO:3 and a mutation of amino acid 257 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said two pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein are a first pair of amino acid mutations by cysteines and a second pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3, and said second pair of amino acid mutations by cysteines is a mutation of amino acid 217 of SEQ ID NO:3 and a mutation of amino acid 253 of SEQ ID NO:3.
  • said wild-type CRALBP protein is the human CRALBP protein of SEQ ID NO:3, and said mutein comprises three pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein, and wherein said three pairs of amino acid mutations by cysteines as compared to said human wild-type CRALBP protein are a first pair of amino acid mutations by cysteines, a second pair of amino acid mutations by cysteines, and a third pair of amino acid mutations by cysteines, wherein said first pair of amino acid mutations by cysteines is a mutation of amino acid 212 of SEQ ID NO:3 and a mutation of amino acid 250 of SEQ ID NO:3, said second pair of amino acid mutations by cysteines is a mutation of amino acid 220 of SEQ ID NO:3 and a mutation of amino acid 254 of SEQ ID NO:3, and said third pair of amino acid mutations by cysteines is a mutation of amino acid 224 of SEQ ID NO:3 and a mutation of
  • said CRALBP mutant protein has an amino acid sequence selected from group consisting of SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, and wherein preferably said CRALBP mutant protein has an amino acid sequence selected from SEQ ID NO: 11 and SEQ ID NO:24, and wherein further preferably said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 11.
  • each of said pair of cysteines forms a disulfide bond, and thus, within said complexes, said CRALBP mutant protein is completely in the oxidized form.
  • said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 11. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 14. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 16. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO: 18. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO:20. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO:22. In a further preferred embodiment, said CRALBP mutant protein has the amino acid sequence of SEQ ID NO:24.
  • said CRALBP mutant protein has the amino acid sequence of SEQ ID NO:26.
  • each of said pair of cysteines forms a disulfide bond, and thus, within said inventive complexes, said CRALBP mutant protein is completely in the oxidized form.
  • said CRALBP mutant protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 11, and wherein said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 forms a disulfide bond.
  • said CRALBP mutant protein consists of an amino acid sequence selected from group consisting of SEQ ID NO: 11, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, and wherein preferably said CRALBP mutant protein consists of an amino acid sequence selected from SEQ ID NO: 11 and SEQ ID NO:24, and wherein further preferably said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11.
  • each of said pair of cysteines forms a disulfide bond.
  • said CRALBP mutant protein is completely in the oxidized form.
  • said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 14. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 16. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 18. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO:20. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO:22. In a further preferred embodiment, said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO:24.
  • said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO:26.
  • each of said pair of cysteines forms a disulfide bond.
  • said CRALBP mutant protein is completely in the oxidized form.
  • said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11, and wherein said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 forms a disulfide bond.
  • said CRALBP protein has an amino acid sequence selected from group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, wherein preferably said CRALBP protein has an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:24, SEQ ID NO:27 and SEQ ID NO:28, and wherein further preferably said CRALBP protein has an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:27 and SEQ ID NO:28, and wherein again further preferably said CRALBP protein has the amino acid sequence of SEQ ID NO: 11, SEQ ID NO: 12, or
  • said CRALBP protein has the amino acid sequence of SEQ ID NO:3. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:4. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO: 11. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO: 12. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO: 14. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO: 16. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO: 18.
  • said CRALBP protein has the amino acid sequence of SEQ ID NO:20. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:22. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:24. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:26. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:27. In a further preferred embodiment, said CRALBP protein has the amino acid sequence of SEQ ID NO:28.
  • said CRALBP protein consists of an amino acid sequence selected from group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28, wherein preferably said CRALBP protein consists of an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:24, SEQ ID NO:27 and SEQ ID NO:28, and wherein further preferably said CRALBP protein consists of an amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:27 and SEQ ID NO:28, and wherein again further preferably said CRALBP protein consists of the amino acid sequence of SEQ ID NO:
  • said CRALBP protein consists of the amino acid sequence of SEQ ID NO:3. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:4. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 11. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 12. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 14. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 16. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 18.
  • said CRALBP protein consists of the amino acid sequence of SEQ ID NO:20. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:22. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:24. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:26. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:27. In a further preferred embodiment, said CRALBP protein consists of the amino acid sequence of SEQ ID NO:28.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand. In a preferred embodiment, said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein. In a preferred embodiment, said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a CRALBP mutant protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wildtype CRALBP protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a CRALBP mutant protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein.
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a CRALBP mutant protein.
  • said complex is a monomeric complex of said CRALBP mutant protein and said cognate ligand.
  • said complex is a monomeric complex of said wild-type CRALBP protein and said cognate ligand.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand. In a preferred embodiment, said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wildtype CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein. In a preferred embodiment, said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a CRALBP mutant protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a CRALBP mutant protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein.
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a CRALBP mutant protein.
  • said complex is a dimeric complex of said CRALBP mutant protein and said cognate ligand.
  • said complex is a dimeric complex of said wild-type CRALBP protein and said cognate ligand.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand. In a preferred embodiment, said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein. In a preferred embodiment, said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a CRALBP mutant protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wildtype CRALBP protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a CRALBP mutant protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a CRALBP mutant protein.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand.
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand. In a further preferred embodiment, said complex is an homo oligomeric complex of said CRALBP protein and said cognate ligand. In a further preferred embodiment, said complex is an homo oligomeric complex of said CRALBP mutant protein and said cognate ligand. In a further preferred embodiment, said complex is an homo oligomeric complex of said wild-type CRALBP protein and said cognate ligand.
  • said oligomeric complex has a molecular weight of at least 500kDa, preferably of at least 600kDa, preferably of at least 720kDa, and preferably a molecular weight of at most 2500kDa, further preferably a molecular weight of at most 2000kDa, and further preferably a molecular weight of at most 1500kDa, or wherein said oligomeric complex has a average diameter of about 18 to 35 nm, preferably of about 20 to 33 nm, further preferably of about 24 to 33 nm, and wherein preferably said oligomeric complex has a average diameter of about 25 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said oligomeric complex has a molecular weight of at least 600kDa, preferably of at least 720kDa, and preferably a molecular weight of at most 2500kDa, further preferably a molecular weight of at most 2000kDa, and further preferably a molecular weight of at most 1500kDa.
  • said oligomeric complex has a average diameter of about 18 to 35 nm, preferably about 24 to 33 nm, and wherein preferably said oligomeric complex has a average diameter of about 25 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 600kDa, preferably of at least 720kDa, and preferably a molecular weight of at most 2500kDa, further preferably a molecular weight of at most 2000kDa, and further preferably a molecular weight of at most 1500kDa, or wherein said oligomeric complex has a average diameter of about 18 to 35 nm, preferably about 24 to 33 nm, and wherein preferably said oligomeric complex has a average diameter of about 25 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 18 to 35 nm, preferably about 20 to 33 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 18 to 35 nm, preferably about 20 to 33 nm, further preferably about 20 to 30 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 20 to 35 nm, further preferably about 23 to 33 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 10 to 18 nm, preferably about 10 tol6 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 10 to 18 nm, preferably about 10 to 16 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 10 to 18 nm, preferably about 10 to 16 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is a dimeric complex of said CRALBP protein and said cognate ligand, wherein said dimeric complex has a average diameter of about 7 to 10 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • said complex is a dimeric complex said wild-type CRALBP protein and said cognate ligand, wherein said dimeric complex has a average diameter of about 7 to 10 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is a dimeric complex said CRALBP mutant protein and said cognate ligand, wherein said dimeric complex has a average diameter of about 7 to 10 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is a monomeric complex of said CRALBP protein and said cognate ligand, wherein said monomeric complex has a average diameter of about 5 to 7 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • said complex is a monomeric complex said wild-type CRALBP protein and said cognate ligand, wherein said monomeric complex has a average diameter of about 5 to 7 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is a monomeric complex said CRALBP mutant protein and said cognate ligand, wherein said monomeric complex has a average diameter of about 5 to 7 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 240 kDa, preferably of at least 300 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 660 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 600 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 500 kDa.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 600kDa, preferably of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2500 kDa, preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 240 kDa, preferably of at least 300 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 660 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 600 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 500 kDa.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 600kDa, preferably of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2500 kDa, preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said wildtype CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 240 kDa, preferably of at least 300 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 660 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 600 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 500 kDa.
  • said complex is an oligomeric complex of said wildtype CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 500kDa, preferably of at least 600kDa, preferably of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said wildtype CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 600kDa, preferably of at least 720 kDa, preferably of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2500 kDa, furthr preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and further preferably a molecular weight of at most 1500kDa.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP proteins within said oligomeric complex are equal or higher than 6 and equal or lower than 18, preferably equal or higher than 8 and and equal or lower than 16, and wherein further preferably said number of said cognate ligands the number of said CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP mutant proteins within said oligomeric complex are equal or higher than 6 and equal or lower than 18, preferably equal or higher than 8 and and equal or lower than 16, and wherein further preferably said number of said cognate ligands the number of said CRALBP mutant proteins are equal.
  • said complex is an oligomeric complex of said wildtype CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said wild-type CRALBP proteins within said oligomeric complex are equal or higher than 6 and equal or lower than 18, preferably equal or higher than 8 and and equal or lower than 16, and wherein further preferably said number of said cognate ligands the number of said wildtype CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP proteins within said oligomeric complex are equal or higher than 20 and equal or lower than 75, preferably equal or higher than 22 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP proteins within said oligomeric complex are equal or higher than 24 and equal or lower than 75, preferably equal or higher than 26 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP proteins are equal.
  • said complex is an oligomeric complex of said wildtype CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said wild-type CRALBP proteins within said oligomeric complex are equal or higher than 20 and equal or lower than 75, preferably equal or higher than 22 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said wild-type CRALBP proteins are equal.
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said wild-type CRALBP proteins within said oligomeric complex are equal or higher than 24 and equal or lower than 75, preferably equal or higher than 26 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said wild-type CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP proteins within said oligomeric complex are equal or higher than 20 and equal or lower than 75, preferably equal or higher than 22 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP proteins within said oligomeric complex are equal or higher than 24 and equal or lower than 75, preferably equal or higher than 26 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP mutant proteins within said oligomeric complex are equal or higher than 20 and equal or lower than 75, preferably equal or higher than 22 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP mutant proteins are equal.
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein the number of said cognate ligands and said CRALBP mutant proteins within said oligomeric complex are equal or higher than 24 and equal or lower than 75, preferably equal or higher than 26 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said CRALBP mutant proteins are equal.
  • said complex is an oligomeric complex of said wildtype CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said wild-type CRALBP proteins within said oligomeric complex are equal or higher than 20 and equal or lower than 75, preferably equal or higher than 22 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said wild-type CRALBP proteins are equal.
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein the number of said cognate ligands and said wild-type CRALBP proteins within said oligomeric complex are equal or higher than 24 and equal or lower than 75, preferably equal or higher than 26 and equal or lower than 60, and wherein further preferably said number of said cognate ligands the number of said wild-type CRALBP proteins are equal.
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 8 to 20 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 10 to 18 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 18 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 20 to 30 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 8 to 20 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 12 to 17 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 24 to 33 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 26 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 8 to 20 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 12 to 16 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a average diameter of about 18 to 32 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), and wherein preferably said oligomeric complex has a average diameter of about 20 to 30 nm, wherein said average diameter is determined by Dynamic Light Scattering (DLS), preferably wherein said average diameter is determined by DLS as described in Example 11 and Table 5.
  • DLS Dynamic Light Scattering
  • said composition comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand.
  • said composition comprises monomeric complexes and homo oligomeric complexes of said CRALBP mutant protein and said cognate ligand.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP mutant protein and said cognate ligand.
  • said composition comprises monomeric complexes and homo oligomeric complexes of said wild-type CRALBP protein and said cognate ligand.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said wild-type CRALBP protein and said cognate ligand.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand. In a preferred embodiment, said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein or a CRALBP mutant protein. In a preferred embodiment, said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a wild-type CRALBP protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein comprises a CRALBP mutant protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a wild-type CRALBP protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein consists of a CRALBP mutant protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein or a CRALBP mutant protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a wild-type CRALBP protein.
  • said complex comprises monomeric complexes and homo oligomeric complexes of said CRALBP protein and said cognate ligand, wherein said CRALBP protein is a CRALBP mutant protein.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11- czs-retinal; (iv) l l-czs-retinol; (v) 9, 13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-c
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11- czs-retinal; (iv) l l-czs-retinol; (v) 9, 13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-c
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- cz.s-retinal and (ii) 1 l-czs-retinal; and wherein preferably said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kD
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- cz.s-retinal and (ii) 1 l-czs-retinal; and wherein preferably said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- cz.s-retinal and (ii) 11-czs-retinal; and wherein said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 preferably forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP mutant protein, wherein said CRALBP mutant protein consists of the amino acid sequence of SEQ ID NO: 11; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9- cz.s-retinal and (ii) 1 l-czs-retinal; and wherein said pair of cysteines of amino acid 212 and 250 of SEQ ID NO: 11 forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP mutant protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11- cz -retinal; (iv) l l-czs-retinol; (v) 9, 13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-re
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11- cz -retinal; (iv) l l-czs-retinol; (v) 9, 13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-re
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein consists of the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- c/.s-retinal and (ii) 11-czs-retinal; and wherein preferably said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein consists of the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- c/.s-retinal and (ii) 11-czs-retinal; and wherein preferably said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein consists of the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- c/.s-retinal and (ii) 11-czs-retinal; and wherein said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a wild-type CRALBP protein, wherein said wild-type CRALBP protein consists of the amino acid sequence of SEQ ID NO:3; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a c/.s-retinoid selected from (i) 9- c/.s-retinal and (ii) 11-czs-retinal; and wherein said complex is an oligomeric complex of said wild-type CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11-cz -retinal; (iv) 11- cz -retinol; (v) 9,13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 11-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11-cz -retinal; (iv) 11- cz -retinol; (v) 9,13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 11-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9-cz.s-retinal and (ii) 11-cz -retinal; and wherein preferably said pair of cysteines of amino acid 232 and 270 of SEQ ID NO: 12 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv'.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 1 l-czs-retinal; and wherein preferably said pair of cysteines of amino acid 232 and 270 of SEQ ID NO: 12 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv'.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said pair of cysteines of amino acid 232 and 270 of SEQ ID NO: 12 preferably forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably where
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 12; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv'.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said pair of cysteines of amino acid 232 and 270 of SEQ ID NO: 12 forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cA-retinal; (ii) 9-cA-retinol; (iii) 11-cz -retinal; (iv) 11- czs-retinol; (v) 9,13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 11-czs-retinol, further
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid, wherein preferably said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 9-cz.s-retinol; (iii) 11-cz -retinal; (iv) 11- czs-retinol; (v) 9,13-di-cz.s-retinal; and (vi) 9,13-di-cz.s-retinol, further preferably wherein said cz.s-retinoid is selected from (i) 9-cz.s-retinal; (ii) 11-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9-cz.s-retinal and (ii) 11-cz -retinal; and wherein preferably said pair of cysteines of amino acid 215 and 253 of SEQ ID NO:28 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein preferably said pair of cysteines of amino acid 215 and 253 of SEQ ID NO:28 forms a disulfide bond, and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said pair of cysteines of amino acid 215 and 253 of SEQ ID NO:28 forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said complex comprises (a) a
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:28; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cz.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said pair of cysteines of amino acid 215 and 253 of SEQ ID NO:28 forms a disulfide bond, and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid, wherein preferably said cv.s-retinoid is selected from (i) 9-cA-retinal; (ii) 9-cA-retinol; (iii) 1 l-czs-retinal; (iv) 11- czs-retinol; (v) 9, 13-di-cv.s-retinal; and (vi) 9, 13-di-cv.s-retinol, further preferably wherein said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 1 l-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid, wherein preferably said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 9-cv.s-retinol; (iii) 11-czs-retinal; (iv) 11- czs-retinol; (v) 9,13-di-cv.s-retinal; and (vi) 9,13-di-cv.s-retinol, further preferably wherein said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 11-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and wherein preferably said oligomeric complex
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 1 l-czs-retinal; and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO:4; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid, wherein preferably said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 9-cv.s-retinol; (iii) 11-czs-retinal; (iv) 11- czs-retinol; (v) 9,13-di-cv.s-retinal; and (vi) 9,13-di-cv.s-retinol, further preferably wherein said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 11-
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid, wherein preferably said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii) 9-cv.s-retinol; (iii) 1 l-czs-retinal; (iv) 11- czs-retinol; (v) 9,13-di-cv.s-retinal; and (vi) 9,13-di-cv.s-retinol, further preferably wherein said cv.s-retinoid is selected from (i) 9-cv.s-retinal; (ii)
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa, and wherein preferably said oligomeric complex
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein preferably said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv'.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 1 l-czs-retinal; and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 720 kDa, preferably of at least 800 kDa, and wherein preferably said oligomeric complex has a molecular weight of at most 2500 kDa, further preferably wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • said composition comprising, preferably consisting of, a complex, wherein said complex comprises (a) a CRALBP protein, wherein said CRALBP protein consists of the amino acid sequence of SEQ ID NO: 27; and (b) a cognate ligand of CRALBP, wherein said cognate ligand is a cv'.s-retinoid selected from (i) 9-cv.s-retinal and (ii) 11-czs-retinal; and wherein said complex is an oligomeric complex of said CRALBP protein and said cognate ligand, wherein said oligomeric complex has a molecular weight of at least 800 kDa, and wherein said oligomeric complex has a molecular weight of at most 2000 kDa.
  • the present invention provides a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, an amino acid sequence selected from group consisting of SEQ ID NO:4, SEQ ID NO: 12, SEQ ID NO:27 and SEQ ID NO:28.
  • the present invention provides a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4.
  • the present invention provides a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO: 12.
  • the present invention provides a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:27.
  • the present invention provides a CRALBP protein, wherein said CRALBP protein comprises, preferably consists of, the amino acid sequence of SEQ ID NO:28.
  • RLBP1 and expression of wild-type CRALBP was analogously effected as described in the prior art (He, X., et al., 2009, PNAS, 106(44): 18545-18550; WO 2017/129555.
  • human RLBP1 cDNA JRAUp969D1020D, SEQ ID NO: 1 was obtained from the German Center for Genomic Research GmbH.
  • the CRALBP overexpression vector construct was obtained by cloning the RLBP1 cDNA into the Ndel and Xhol sites of the pET-28a(+) vector following the protocol of “StreamLined Restriction Digestion, Dephosphorylation and Ligation” (Promega) leading to the pET-28a(+) CRALBP overexpression plasmid (SEQ ID NO:2). Incubations were carried out at 37°C and 750 rpm (Thermomixer Compact, Eppendorf) for 2.25h, inactivation at 74°C for 15min, separation via 1% agarose gel and extraction of the desired cutting fragments with the “Wizard SV Gel and PCR Clean-Up System” from Promega according to the user manual.
  • Thermosensitive Alkaline Phosphatase was used only for the digestion of the pET-28a(+) target vector but not for the digestion of the RLBP1 cDNA (JRAUp969D1020D).
  • BL21(DE3) strains of E. coli (Invitrogen) were transformed with the pET-28a(+) CRALBP overexpression plasmid (SEQ ID NO:2), and were cultured overnight with agitation at 37 °C in 120 mL LB medium containing 30 mg/mL kanamycin. The overnight culture was used to inoculate 6 L of LB medium (30 mg/mL kanamycin).
  • the culture was grown at 20 °C to an ODeoo of 0.7 and then was induced with 1 mM isopropyl-thiogalacto- pyranoside for 16 h.
  • Cells were harvested by centrifugation at 5000 g for 45 min and were resuspended in 250 mL of ice-cold lysis buffer (20 mM imidazole; 100 mMNaCl; 20 mM Tris- HC1, pH 7.4; 1% wt/vol Triton X-100).
  • the cells were disrupted by ultrasonication for 20 min, and the lysate comprising human wild-type CRALPB (SEQ ID NO:3) in the form of its His-tag adduct (SEQ ID NO:4) which was centrifuged at 20,000g for 35 min to remove debris.
  • human wild-type CRALPB SEQ ID NO:3
  • His-tag adduct SEQ ID NO:4
  • Point mutations were introduced sequentially by site-directed mutagenesis in pET-28a(+) CRALBP overexpression plasmid (SEQ ID NO:2) according to the instructions described in the QuikChange kit from Stratagene.
  • the corresponding primer sequences, the PCR reaction mixtures and the temperature protocol used to produce the di-cys mutant CRALBP A212C:T250C are depicted in Table 1 and Table 2 respectively.
  • Table 1 mutated positions are identified by underlined-blocks.
  • T250C the point mutation directly leads to the formation of a novel restriction site.
  • an additional silent mutation was introduced (see underlined and cursive).
  • nucleotide sequence of SEQ ID NO:2 was used as starting template in the site- directed PCR. After sequential PCR reactions the resulting expression plasmid pET-28a(+) mutant RLBP1 (SEQ ID NO:9) comprising the nucleotide sequence of SEQ ID NO: 10 and encoding for the amino acid SEQ ID NO: 11 of the di-cys mutant CRALBP A212C:T250C was obtained.
  • BL21(DE3) cells transformed with and containing the expression plasmid pET-28a(+) mutant RLBP1 (SEQ ID NO:9) comprising the nucleotide sequence of di-cys mutant CRALBP A212C:T250C (SEQ ID NO: 10) were cultured overnight with agitation at 37 °C in 120 mL LB medium containing 30 mg/mL kanamycin. The overnight culture was used to inoculate 6 L of LB medium (30 mg/mL kanamycin). The culture was grown at 20 °C to an ODeoo of 0.7 and then was induced with 1 mM isopropyl -thiogalacto-pyranoside for 16 h.
  • Cells were harvested by centrifugation at 5000 g for 45 min and were resuspended in 250 mL of ice-cold lysis buffer (20 mM imidazole; 100 mM NaCl; 20 mM Tris-HCl, pH 7.4; 1% wt/vol Triton X-100). The cells were disrupted by ultrasonication for 20 min, and the lysate comprising the di-cys mutant CRALBP A212C:T250C of SEQ ID NO: 11 in the form of its His-tag adduct (SEQ ID NO: 12) was centrifuged at 20,000g for 35 min to remove debris.
  • Native CRALBP binds both 1 l -c/.s-retinal and 9-cv.s-retinal ligands with high affinity in the low nanomolar range.
  • CRALBP’ s mobile gate moiety adopts its ‘closed’ conformational state with helixl2 and helixlO being within van der Waals distance of one another.
  • the side-chain sulphur atoms of the mutated residues C212 and C250 oppose each other at 2.4 A distance within the interface formed by the two helices (see Figure 1).
  • silica cysteine mutagenesis was carried out in order to identify possibly stabilizing disulfide bridges in CRALBP, other than the above described di-cysteine mutant A212C:T250C (SEQ ID NO: 11).
  • a truncated model was created from the X-ray structural model of wild-type CRALBP with bound 1 l -c/.s-retinal (PDB entry 3HY5).
  • Two sequence regions of wild-type CRALBP (SEQ ID NO:3), namely amino acid residues 204-229 of SEQ ID NO:3 and amino acid residues 244-261 of SEQ ID NO: 3 were defined by editing the original model.
  • the FoldX V5 “BuildModel” command which implements a probabilitybased rotamer library of its own, was used to create in silico eight CRALBP mutant proteins comprising one, two or three pairs of cysteines mutations containing models including the di- cys mutant A212C:T250C.
  • Table 3 lists said identified CRALBP mutant proteins as well as their amino acid and nucleic acid sequences.
  • Interface A 2 is the total solvent accessible surface area in square Angstroms; Interface area in A 2 , calculated as difference in total accessible surface areas of isolated and interfacing structures divided by two.
  • A'G indicates the solvation free energy gain upon formation of the interface, in kcal/mol. Any A‘G value that is reported to be more negative than the reference value of -11.2 kcal/mol is considered to effect a further stabilization of the corresponding mutant in comparison to wild-type CRALBP.
  • Figure 2 shows individually the close up view of the in silico model of the mobile gate region of the four described mono di-cysteine mutants of CRALBP with the position of the formed disulfide bonds highlighted as sticks
  • Figure 3 the close up view of the in silico model of the mobile gate region of each of the three double and the triple di-cysteine mutants of CRALBP with the position of the formed disulfide bonds highlighted as sticks are shown.
  • the superposition of all in silico di-cysteine mutant models showing four possible described disulfide bonds across the mobile gate of CRALBP is shown in Figure 4.
  • nucleic acid sequences as well as the amino acid sequences of the further identified di-cys CRALBP mutants are described in Table 3.
  • the cloning of the corresponding mutant RLBP 1 gene sequences and the expression of the corresponding di-cys CRALBP mutant proteins is effected analogously as described in Example 1 and 2.
  • the purification of these further identified di-cys CRALBP mutants is effected as described in Example 5 below.
  • the lysates comprising the wild-type CRALBP of SEQ ID NO:3 in the form of its His- tag adduct (SEQ ID NO:4) obtained in Example 1 and the di-cys mutant CRALBP A212C:T250C of SEQ ID NO: 11 in the form of its His-tag adduct (SEQ ID NO: 12) obtained in Example 2 were both purified from supernatant by affinity chromatography on 10 mL of Ni- NTA SUPERFLOW (Qiagen) according to the manufacturer’s instructions.
  • the lysates were loaded on the column previously equilibrated in lysis buffer, washed with lysis buffer, and were eluted in 35 mL of elution buffer (20 mM Tris-HCl, pH 7.4; 200 mM imidazole; 100 mM NaCl).
  • Typical yields of 35-40 mg of pure wild-type CRALBP and of pure di-cys mutant CRALBP A212C:T250C respectively were obtained as judged by SDS/PAGE and determined using the colorimetric bicinchoninic acid assay (Pierce Chemical Company). Either the N- terminal his-tag constructs or the his-tag-cleaved CRALPB proteins were used for the complex formation” as described in Example 6.
  • the (His)e-tag was cleaved by adding 20 units of thrombin protease (GE Healthcare) and subsequent incubation at 4 °C overnight. The protein solution was then passed through a Ni-NTA column previously equilibrated in lysis buffer to remove uncleaved material. The flowthrough was concentrated by Centriprep-10 (Millipore) to 20 mg/mL. Cleavage of the His-tag led to CRALPB protein of SEQ ID NO:27 in case of the wild-type CRALPB, and to CRALPB protein of SEQ ID NO:28 in case of the A212GT250C CRALBP mutant protein. Cognate ligand-complexes of CRALBP were separated on a Superdex® 200 26/60 gel filtration column (GE Healthcare).
  • the samples were incubated for 30 min at 4°C and then centrifuged at 15,000 g for 10 min.
  • the samples were concentrated using a Vivaspin 15R Hydrosart (Sartorius) to 30-50 mg/ml of protein with three washes in buffer (10 mM Tris-HCl, 100 mM NaCl, pH 7.5). Finally, unbound retinoid was removed from the ligand complexes by gel filtration chromatography (GFC).
  • GFC gel filtration chromatography
  • Figure 5B shows the typical UV/Vis absorption trace at 280 nm featuring said four peaks.
  • the order of the peaks is as follows: the first peak from left to right corresponds to the super high molecular weight (SHMW) fractions, the second peak corresponds to the high molecular weight (HMW) fraction, the third peak corresponds to dimeric, and the fourth peak to monomeric fractions, respectively.
  • UV-Vis absorption spectra of monomeric wild type CRALBP and of the A212C:T250C mutant in complex with 9-cis retinal were used to determine the ligand loading of the monomeric complexes.
  • the absorption spectra were normalized to the maximum absorption, of the protein at approximately 280 nm. According to Crabb et al. (Crabb JW. et al., (1998), Protein Sci. 7(3):746-57) the absorption maximum at 280 nm corresponds to the protein concentration, and the one at 400 nm to bound 9-cis retinal.
  • Photoisomerization assays of c/.s-retinal and its complexes with wild-type CRALBP or with di-cysteine mutant A212C:T250C of CRALBP were performed essentially as described by Saari et al. (Saari JC and Bredberg DL, (1978), J Biol Chem. 262(16):7618-22).
  • the gel permeation chromatography purified ligand complexes were diluted to 26 pM in (GFC) buffer (lOmM Hepes, 100 mM NaCl, pH 7.5) and equimolar amounts of BSA were added to avoid protein precipitation through the light induced formation of free all-/ra//.s-retinal.
  • the samples were exposed with a 100-W daylight bulb to an illuminance of 380 lux (Voltcraft MS- 1300 Luxmeter) at room temperature in the darkroom. Simultaneously UV/Vis absorption spectra were collected every 180 seconds for 3600 sec in total using the Evolution array UV/Vis spectrophotometer (Thermo Scientific). For photoisomerization experiments of the oxidized mutant A212C:T250C or the wild-type CRALBP, 5mM oxidized glutathione was added to the preformed complexes and the mixtures were kept overnight at 4°C.
  • the introduction of the A212CT250C double mutation represents an engineered redox-sensitive on-off switch into human CRALBP allowing for a reversible turning on and off of CRALBP’ s mobile gate functionality.
  • the two mutations are located at adjacent positions in the mobile gate’s interface of CRALBP allowing for the formation of an intramolecular disulfide bond under oxidizing conditions and to regain the gate’s native functionality under reducing conditions.
  • the photo-isomerization assay of the oxidized state of the A212C:T250C: l l-cz -retinal complex reveals increased photoprotection for bound l l -cv.s- retinal, while the reduced state restores CRALBP’ s native in vitro photosensitivity.
  • the dynamic light scattering (DLS) measurements indicate that the sample peaks obtained from gel filtration represent discrete populations of inventive compositions and complexes, respectively.
  • the average size distribution in diameter for the monomeric complex of wild-type CRALBP with 9-cv.s-retinal is 6.45 ⁇ 0.76 nm, for the dimeric complex 7.07 ⁇ 0.29 nm, for the HMW 12.89 ⁇ 0.89 nm, and for the SHMW 21.43 ⁇ 7.07 nm, respectively and of di-cysteine mutant A212C:T250C CRALBP with 9-cv.s-retinal is 6.50 ⁇ 1.50 nm, for the dimeric complex 8.72 ⁇ 2.41 nm, for the HMW 13.50 ⁇ 0.47 nm, and for the SHMW 28.28 ⁇ 2.13 nm, respectively (see Figure 11, Panel A and Panel B).
  • mice with a conventional knockout of the retinal pigmented epithelium protein 65 kDa gene were described previously (Redmond, T.M., et al. 1998, Nat Genet. 20(4):344- 51). Young adult animals of either sex (6-10-week-old) were used. Animals were provided with standard chow (LabDiet 5053; LabDiet, Purina Mills) and maintained under a 12 h light / 12 h dark cycle. Mice were dark-adapted overnight before physiological recordings.
  • the RPE65-/- model chosen in this study for readout represents the most widely used mouse model for monitoring retinitis pigmentosa (RP) as well as for leber congenital amaurosis (LCA) related defects of the retina.
  • RP retinitis pigmentosa
  • LCA leber congenital amaurosis
  • the genetic defect abolishes the trans- o-cis re- isomerization activity of RPE65 in the visual cycle resulting in a very low c/.s-retinoid background.
  • RPE65-/- thus is considered the prototypic animal model for chromophore deficiencies in retinal dystrophies.
  • mice Six to ten week old mice are typically chosen for the ex vivo electroretinogram (ERG) experiments because at this age the rod and cone photoreceptors are, despite the lack of endogenously produced cis-retinoids, still viable and most suitable for reloading experiments using exogeneosly added czs-retinal.
  • ERG electroretinogram
  • the final concentration of the 9-cis retinal was estimated to be about 162 pM.
  • a whole isolated RpedS ⁇ mouse retina on filter paper was incubated in a Petri dish with 2 ml of this solution in oxygenated dark container for 4-4.5 h in the dark, at RT.
  • Some untreated control retinas from the same mouse line were incubated 4-4.5 h in the same L15 solution without CRALBP and retinoid.
  • a comparable amount of pure 9-cis retinal in L15 (about 135 pM, dissolved in 0.1% EtOH) was applied to the retina for 1-1.5 h. The tissue was then transferred to the perfusion chamber for ex vivo ERG recordings, as described below.
  • RPE65-deficient mice were dark-adapted overnight, sacrificed by CO2 asphyxiation, and a whole retina was removed from each mouse eyecup under infrared illumination.
  • the retina was mounted on filter paper with the photoreceptor side up and placed in a perfusion chamber between two electrodes connected to a differential amplifier (Vinberg, F., et al., 2014, Vision Res. 2014;101 : 108-17).
  • the tissue was perfused with Locke’s solution containing 112.5 mM NaCl, 3.6 mM KCl, 2.4 mM MgCh, 1.2 mM CaCh, 10 mM HEPES, pH 7.4, 20 mM NaHCCh, 3 mMNa succinate, 0.5 mM Na glutamate, 0.02 mM EDTA, and 10 mM glucose.
  • This solution was supplemented with 2 mM L-glutamate and 10 pM DL-2-amino-4-phosphonobutyric acid (DL-AP4) to block postsynaptic components of the photoresponse (Sillman, A.J., 1969, Vision Res.
  • ERGs intraretinal field potentials
  • the a-wave sometimes called the “late receptor potential,” reflects the general physiological health of the photoreceptors in the outer retina.
  • the b-wave reflects the health of the inner layers of the retina, including the ON bipolar cells and the Muller cells (Miller, R.F., 1970, J Neurophysiol. 33(3):323-41).
  • the mounted retinae are stimulated with short light flashes with the electric responses of the retinae being monitored in dependency of the applied intensities of the light flashes.
  • Figure 12 the obtained ex vivo ERG photoresponse curves for RPE65-/- and wild-type retinae are shown as semi-logarithmic graph where the y-axis represents the amplitude of the photoresponse in pV while the x-axis (logarithmic scale) represents the light intensity in photons per square pm.
  • the position of the inflection point of each curve in relation to the x- axis thus correlates with the light-sensitivity of the retina, while the maximum of the curve with realation to the y-axis correlates with the amount of light sensitive photoreceptors of the retina.
  • rod ERG a-wave flash sensitivity was first determined in the dark, as follows: 5f - A/(A ma . ⁇ I) , where A is the rod a-wave dim flash response amplitude, A max is the maximal response amplitude for that eye produced with the brightest green light stimulus (23.5 cd-s/m 2 ), and I is the flash strength of dim flash response (in cd-s m' 2 ).
  • the rod pigment was then near completely bleached by a 35-s exposure to bright light delivered by a 520 nm LED focused at the surface of the mouse eye cornea.
  • the bleaching fraction was estimated by the following formula:
  • F 1 - exp(-/ 7), where F is the fraction of pigment bleached, t is the duration of the light exposure (in seconds), /is the bleaching light intensity of 520 nm LED light (1.3 x 10 8 photons pm' 2 s' 1 ), and P is the photosensitivity of mouse rods at the wavelength of peak absorbance (5.7 x 10-9 pm 2 , Woodruff, M.L., et al., 2004, The Journal of Physiology, 557:821-828). After the bleach, the recovery of rod response was followed in darkness for up to 1 h. Mice were re-anesthesized with a lower dose of ketamine ( ⁇ 1/3 of the initial dose) in the middle of that period. If necessary, a 1 : 1 mixture of PBS and Gonak solutions was gently applied to eyes with a plastic syringe to protect them from drying and maintain contacts with the recording electrodes.
  • Rpe65-/- mice are dark adapted, anesthetized and mouse body temperature has to be maintained at 37 °C as described in Examples 12 and 13 respectively.
  • the intravitreal injections are performed by hand using a Hamilton syringe under the microscope and infrared illumination with 2 pl of the drug complex containing ⁇ 3.2 nmol of 9-cv.s-retinal being injected in one eye and an equal volume of PBS solution, as a control, into the other eye.
  • the total amount of injected retinoid is estimated to exceed the average rhodopsin content of a healthy adult mouse eye by at least a factor of 5-6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions destinées à être utilisées dans des méthodes de prévention ou de traitement de maladies ou de troubles rétiniens d'un animal ou d'un être humain, lesdites compositions comprenant des complexes contenant (a) une protéine CRALBP et (b) un ligand parent de CRALBP.
PCT/EP2023/082964 2022-11-24 2023-11-24 Agents thérapeutiques à base de cralbp dirigés contre des troubles rétiniens Ceased WO2024110625A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22209321 2022-11-24
EP22209321.3 2022-11-24

Publications (1)

Publication Number Publication Date
WO2024110625A1 true WO2024110625A1 (fr) 2024-05-30

Family

ID=84361565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/082964 Ceased WO2024110625A1 (fr) 2022-11-24 2023-11-24 Agents thérapeutiques à base de cralbp dirigés contre des troubles rétiniens

Country Status (1)

Country Link
WO (1) WO2024110625A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082622A2 (fr) * 2003-03-14 2004-09-30 University Of Washington Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
WO2013134867A1 (fr) 2012-03-01 2013-09-19 Qlt Inc. Schémas et procédé thérapeutiques utilisés pour améliorer la fonction visuelle dans les troubles de la vue associés à une carence en rétinoïdes endogènes
WO2013164793A2 (fr) * 2012-05-04 2013-11-07 Novartis Ag Vecteurs viraux pour le traitement de la dystrophie rétinienne
WO2016108219A1 (fr) * 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Procédés de traitement de maladies rétiniennes
WO2017129555A1 (fr) 2016-01-25 2017-08-03 Universität Bern Nanosphères de protéines de type sec14 et ligands parents
WO2022243386A2 (fr) 2021-05-19 2022-11-24 Universität Bern Protéines mutantes de cralbp sensibles à l'oxydo-réduction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082622A2 (fr) * 2003-03-14 2004-09-30 University Of Washington Substituts de retinoides et agonistes d'ospine et methodes d'utilisation correspondantes
WO2013134867A1 (fr) 2012-03-01 2013-09-19 Qlt Inc. Schémas et procédé thérapeutiques utilisés pour améliorer la fonction visuelle dans les troubles de la vue associés à une carence en rétinoïdes endogènes
WO2013164793A2 (fr) * 2012-05-04 2013-11-07 Novartis Ag Vecteurs viraux pour le traitement de la dystrophie rétinienne
WO2016108219A1 (fr) * 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Procédés de traitement de maladies rétiniennes
WO2017129555A1 (fr) 2016-01-25 2017-08-03 Universität Bern Nanosphères de protéines de type sec14 et ligands parents
WO2022243386A2 (fr) 2021-05-19 2022-11-24 Universität Bern Protéines mutantes de cralbp sensibles à l'oxydo-réduction

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
ADAMS P.D. ET AL., ACTA CRYSTALLOGR. D BIOL. CRYSTALLOGR., vol. 66, 2010, pages 213 - 21
ANNEKE I. ET AL., PROGRESS IN RETINAL AND EYE RESEARCH, vol. 27, 2008, pages 391 - 419
BERGER, W. ET AL., PROG RETINA EYE RES, vol. 29, 2010, pages 335 - 375
BOLZE, C.S. ET AL., JACS, vol. 136, no. 1, 2014, pages 137 - 146
CIDECIYAN A.V. ET AL., PROG RETIN EYE RES., vol. 29, 2010, pages 398 - 427
COLLINS MD.MAO GE., ANNU REV PHARMACOL TOXICOL, vol. 39, 1999, pages 399 - 430
CRABB JW. ET AL., PROTEIN SCI., vol. 7, no. 3, 1998, pages 746 - 57
CROSS, N. ET AL., CLIN OPHTHALMOL., vol. 16, 2022, pages 2909 - 2921
DAICH VARELA M. ET AL., BR. J. OPHTHALMOL., vol. 106, 2022, pages 445 - 451
DEN HOLLANDER ET AL., PROG RETIN EYE RES., vol. 27, 2008, pages 391 - 419
GOLOVLEVA I. ET AL., J. BIOL. CHEM., vol. 278, no. 14, 2003
HARTONG, D.T. ET AL., LANCET, vol. 368, 2006, pages 1795 - 1809
HE, X. ET AL., PNAS, vol. 106, no. 44, 2009, pages 18545 - 18550
HOLT, R. ET AL., EXP EYE RES., vol. 132, 2015, pages 161 - 173
KISER, P.D. ET AL., CHEM. REV., vol. 114, 2014, pages 194 - 232
KISER, P.D. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 296, 2021, pages 100072
KOENEKOOP, R. K. ET AL., LANCET, vol. 384, 2014, pages 1513 - 1520
KOLESNIKOV, A.V., J NEUROSCI., vol. 30, no. 33, 2010, pages 11222 - 31
KUMARAN N. ET AL., BR. J. OPHTHALMOL., vol. 101, 2017, pages 1147 - 1154
LITTINK ET AL., OPHTHALMOLOGY, vol. 119, 2012, pages 1899 - 906
LIU TIANYUN ET AL: "Structural insights into the cellular retinaldehyde-binding protein (CRALBP)", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 61, no. 2, 24 August 2005 (2005-08-24), US, pages 412 - 422, XP093038714, ISSN: 0887-3585, DOI: 10.1002/prot.20621 *
MAEDA, T. ET AL., HUM. MOLEC. GENET., vol. 18, 2009, pages 2277 - 2287
MAEDA, T. ET AL., INVEST OPHTHALMOL VIS SCI., vol. 50, no. 9, 2009, pages 4368 - 78
MILLER, R.F., J NEUROPHYSIOL., vol. 33, no. 3, 1970, pages 323 - 41
MOISEYEV, G. ET AL., PROC. NAT. ACAD. SCI., vol. 102, 2005, pages 12413 - 12418
MUKHERJEE S ET AL., CLIN INTERV AGING., vol. 1, no. 4, 2006, pages 327 - 48
NYMARK, S., J PHYSIOL., vol. 15, no. 567, 2005, pages 923 - 938
PALCZEWSKI K., TRENDS PHARMACOL SCI, vol. 31, 2010, pages 284 - 295
PASKOWITZ, D.M. ET AL., BR J OPHTHALMOL., vol. 90, no. 8, 2006, pages 1060 - 6
PETRUKHIN, K. ET AL., DRUG DISCOVERY TODAY:THERAPEUTIC STRATEGIES, vol. 10, no. 1, 2013, pages e11 - e20
PIRI, N. ET AL., TAIWAN J. OPHTHALMOL., vol. 11, no. 4, 2021, pages 348 - 351
RAFAEL, C. ET AL., INVEST. OPHTHALMOL. VIS. SCI., vol. 51, no. 10, 2010, pages 5304 - 5313
REDMOND, T.M. ET AL., NAT GENET., vol. 20, no. 4, 1998, pages 344 - 51
SAARI JCBREDBERG DL, J BIOL CHEM., vol. 262, no. 16, 1978, pages 7618 - 22
SCHATZ ET AL., OPHTHALMOLOGY, vol. 118, 2011, pages 888 - 94
SCHYMKOWITZ J. ET AL., NUCLEIC ACIDS RES., vol. 1, no. 33, 2005, pages W382 - 8
SHINTANI K. ET AL., OPTOMETRY, vol. 80, 2009, pages 384 - 401
SILLMAN, A.J., VISION RES., vol. 9, 1969, pages 1435 - 1442
SIQUEIRA, R.C. ET AL., RETINA., vol. 31, 2011, pages 1207 - 14
STARGARDT, K., ALBRECHT VON GRAEFES ARCH. KLIN. EXP. OPHTHAL., vol. 71, 1909, pages 534 - 549
TONG, W. ET AL., FRONTIERS IN NEUROSCIENCE, 2020, Retrieved from the Internet <URL:https://www.frontiersin.org/articles/10.3389/fnins.2020.00262>
TRAVIS, GH. ET AL., ANNU REV PHARMACOL TOXICOL, vol. 47, 2007, pages 469 - 512
VINBERG, F. ET AL., VISION RES., vol. 101, 2014, pages 108 - 17
WOODRUFF, M.L. ET AL., THE JOURNAL OF PHYSIOLOGY, vol. 557, 2004, pages 821 - 828

Similar Documents

Publication Publication Date Title
AU2021245195B2 (en) Identification of Channelopsin-2 (Chop2) mutations and methods of use
Zeitz et al. Identification and functional characterization of a novel rhodopsin mutation associated with autosomal dominant CSNB
US9676836B2 (en) cDNA-derived nucleic acids encoding red-shifted channelrhodopsins
JP7299632B2 (ja) 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化
Ferrini et al. CRYBA3/A1 gene mutation associated with suture-sparing autosomal dominant congenital nuclear cataract: a novel phenotype
JP2025123277A (ja) キメラロドプシンをコードする核酸コンストラクト
Yang et al. Dyschromatopsia: a comprehensive analysis of mechanisms and cutting-edge treatments for color vision deficiency
JP2018509909A (ja) 陰イオンチャネルロドプシンの組成物及び使用方法
US20180305417A1 (en) High-efficiency, sodium-specific, blue-shifted channelrhodopsins
Valleix et al. H244R VSX1 is associated with selective cone ON bipolar cell dysfunction and macular degeneration in a PPCD family
WO2024110625A1 (fr) Agents thérapeutiques à base de cralbp dirigés contre des troubles rétiniens
Bownds et al. Rhodopsin content of frog photoreceptor outer segments
Silva et al. A missense mutation in GUCY2D acts as a genetic modifier in RPE65-related Leber congenital amaurosis
WO2021081395A1 (fr) Méthodes de traitement de patients présentant des mutations de cfh avec des protéines de cfh de recombinaison
US20240101637A1 (en) Compositons and methods for use of kalium channel rhodopsins
WO2022059736A1 (fr) Composition destinée au traitement ou à la prévention de maladies, de troubles ou d&#39;états associés à un stress du réticulum endoplasmique ou au rétinal tout-trans, à la protection de l&#39;épaisseur rétinienne, ou à la suppression de la réduction de l&#39;épaisseur rétinienne ou de la progression de la réduction de l&#39;épaisseur rétinienne
Singh et al. Mitochondria and Eye
US20190367564A1 (en) Compositions and methods for use of anion channel rhodopsins
Berson Albert & Jakobiec's Principles & Practice of Ophthalmology
Leung et al. Genetic pathways in retinal degenerations and targets for therapy
Allen A clinical and molecular genetic investigation of X-linked Congenital Stationary Night Blindness
MOLDAY et al. photoreceptor cells and Stargardt macular degeneration
MOLDAY et al. macular degeneration
Kaushal et al. Rhodopsin Mutations in Sectorial Retinitis Pigmentosa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23810094

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23810094

Country of ref document: EP

Kind code of ref document: A1